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Abstract
Isoelectric focusing of serum on polyacrylamide gels
shows a doublet band, known as cystic fibrosis protein, at
an isoelectric point of 8.46+0.05, associated with
expression of the CF gene.
An antiserum (anti-IEF) produced in guinea pigs
against the portion of isoelectric focusing gel containing
the cystic fibrosis protein showed elevated levels of a
serum protein in cystic fibrosis homozygotes, intermediate
levels in heterozygotes and low levels in healthy
controls. Immunoassay of serum samples, using two
different batches of anti-IEF, correctly identified 94% of
CF genotypes.
Biochemical studies of the serum protein, identified
by anti-IEF, showed it to have several different
properties to those ascribed to cystic fibrosis protein.
Therefore, the protein defined immunologically by anti-IEF
was called cystic fibrosis antigen.
Granulocytes from cystic fibrosis homozygotes and
heterozygotes, healthy controls and chronic myeloid
leukaemia patients were shown to contain high levels of
cystic fibrosis antigen in their cytosolic fraction.
Immunisation of guinea pigs with a chronic myeloid
leukaemia granulocyte lysate produced an antiserum
(anti-CML) which recognised the same protein in CF serum
as anti-IEF.
x i i i
Somatic cell hybrids were produced from a mouse
stem-cell line and chronic myeloid leukaemia granulocytes.
Segregation analysis for the expression of cystic fibrosis
antigen assigned the gene to chromosome 1.
Monoclonal antibodies were produced against cystic
fibrosis antigen and a two-site sandwich enzyme-1inked
immunoabsorbent assay developed. Comparative immunoassays
of cystic fibrosis antigen using polyclonal or monoclonal
antibodies showed highly significant correlations with
the same elevated levels of antigen as previously observed
in the presence of the cystic fibrosis gene. In order to
test whether the elevated cystic fibrosis antigen present
in sera from cystic fibrosis homozygotes and heterozygotes
was a consequence of granulocyte proliferation, a large
series of samples including patients with non-CF
respiratory disorders was tested. Simultaneous measurement
was made of another granulocyte derived serum protein,
lactoferrin, and the acute phase reactant, C-Reactive
protein. Attempts to discriminate the cystic fibrosis
homozygotes from the heterozygotes and the heterozygotes
from the controls were unsuccessful, even when ratios of
cystic fibrosis antigen to lactoferrin and C-Reactive
protein were examined. The level of cystic fibrosis
antigen in the heterozygotes was significantly elevated
while, lactoferrin, C-Reactive protein and granulocyte
levels were similar to those of the healthy controls
suggesting that there is an association between cystic




Cystic fibrosis (CF) is a common genetic disease
which presents a widespread health problem throughout the
world. Continuing improvements in recognition and
treatment of the disease has transformed CF from a fatal
disease of early childhood to a chronic disorder
persisting through childhood and into adult life. Patients
usually present in the first year of life, with failure to
grow normally, maldigestion and repeated severe
respiratory infections. In some cases symptoms are milder
and diagnosis may be delayed until later childhood or even
into adult life. Although the course of the disease can be
variable from patient to patient, increased life
expectancy may be attributed to early diagnosis and
improved medical treatment.
1.1. Clinical features.
(Goodchild and Dodge, 1985)
Most of the pathology observed in CF results from
abnormalities in the mucous and serous secretions. The
mucus is very sticky and leads to blockage of ducts,
causing obstruction in a number of organs, particularly
the lungs and pancreas. The serous seretions are
abnormally concentrated and high levels of sodium and
chloride are present in the sweat and saliva. Although
clinically the least serious problem, elevated sweat
sodium and chloride concentration is the undisputed
indicator of CF.
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The onset of respiratory symptoms may occur at any
time after birth but frequently occurs before the end of
the first year. Repeated infection causes progressive
damage to the lungs. In infants Staphylococcus aureus is
the most common pathogen of the respiratory tract,
however, in later stages of the disease Pseudomonas
aeruginosa, especially the slime producing mucoid
variants, often become prevalent. In the upper respiratory
tract, sinus infections and nasal polyps often occur.
Advanced pulmonary disease is often accompanied by
hyperinflation of the chest and accompanied by severe
cough, purulent sputum, shortness of breath, weight loss
and general loss of energy. The cause of death is
frequently as a result of pneumonia, hypoxaemia, cor
pulmonale and exhaustion as a result of the prolonged
period of respiratory insufficiency.
Pancreatic insufficiency occurs in approximately 90%
of patients. In untreated children, severe steatorrhea,
poor weight gain and abdominal distension are
characteristic clinical findings. Meconium ileus
(intestinal obstruction) occurs in 10-15% of children at
birth. Obstruction of the large and small intestine caused
by fecal mucus plugs, may occur occasionally in later
life.
Evidence of liver disease is common in CF although it
rarely presents clinical problems. The incidence of
intrahepatic biliary obstruction increases with increased
age.
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Abnormalities of the salivary glands are related to
the mucus content of secretions. They show marked
retention of secretions, dilation of acini and some
f ibrosis .
In CF patients growth is slow and skeletal and sexual
maturation are often delayed. Most males are sterile due
to early obstruction of the vas deferens and fertility is
reduced in females. Hyperglycaemia is more common in older
patients with CF than in the general population. The
severe malabsorption associated with the disease can
result in nutritional deficiencies related to fat soluble
vitamins and trace elements.
1.2. Genetics and Distribution.
The incidence of CF in Caucasian populations has been
estimated at 1/2500 from new-born screening data (Wilcken
et a 1 . 1983; Heeley, 1983), with a carrier rate of 1/25.
In other ethnic groups the incidence of CF is much rarer
(Talamo et a 1 ., 1983 ).
Autosomal recessive inheritance is indicated as the
mode of inheritance. Much evidence supports the existence
of a single mutant locus (Romeo, 1984). This is further
confirmed by recent molecular biological studies (Beaudet
et a 1 ., 1986). The high incidence of heterozygotes in
Caucasians has led to the proposition that there is some
heterozygote advantage which maintains this high incidence
of the CF gene in these populations (Danks et a 1 ., 1965 ;
Knudson et a 1 >, 1967). However no conclusive evidence has
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been presented on this matter.
The CF gene has been assigned to chromosome 7 by
co-segregation of the gene with linked polymorphic
markers. A genetic variation in the serum level of the
enzyme paraoxanase (PON) was initially identified as being
linked to CF (Eiberg et al., 1985). A CF linked
restriction-fragment length polymorphism (RFLP) was
identified by L-C Tsui et a 1 . ( 1985 ). Several other
laboratories tested other chromosome 7 RFLP's and also
found linkage to CF (White et a 1 ., 1985; Knowlton ^t
aj.,1985; Wainwright et a 1., 1985). The CF locus has been
more specifically assigned to the long arm of chromosome
7, probably between 7q21 and 7q31 (White et a 1., 1985 )
1.3. Prenatal Diagnosis.
Many attempts have been made to develop an accurate
and reliable test for the prenatal diagnosis of CF. Early
tests included the observation of metachromasia in
cultured fibroblasts (Danes and Beam, 1968), measurement
of mucociliary inhibitor in amniotic fluid and cultured
amniotic fluid cells (Bowman et a 1 ., 1973 ) and measurement
of a-mannosidase in amniotic fluid (Hosli and Vogt, 1979a).
Nadler and Walsh (1980) reported that titration of
amniotic fluid supernatant against the artificial
substrate 4-methylumbe11iferylguanidinobenzoate (MUGB)
showed significantly depressed values with CF homozygotes.
This work, in both retrospective and prospective studies,
showed affected fetuses with values of at least two
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standard deviations below the mean for normals.
Examination of isoenzyme patterns of MUGB-protease
after isoelectric focusing further improved this
discrimination (Walsh and Nadler, 1980). However, other
laboratories could not repeat these observations (Brock
and Hayward, 1982; 1983). It seems that MUGB measures an
esterolytic component of albumin and other plasma proteins
(Branchini et a 1 ., 1982 ; Schwartz, 1982).
1.3.1. Microvillar enzymes in amniotic fluid.
In 1983 Carbarns et a 1. reported that the activities
of two microvillar enzymes, ^-glutamyl transpeptidase
(GGTP) and aminopeptidase-M (APM) were depressed in the
amniotic fluid supernatant where the fetus had CF. This
finding was soon confirmed (Baker and Dann, 1983) and the
measurement of microvillar disaccharidases such as
sucrase, lactase, maltase and trehalase were also
considerably reduced in association with a CF fetus (van
Diggelen et a 1 ., 1983). The levels of GGTP and APM have
been further studied in control amniotic fluid and have
been shown to decrease with advancing gestation (Brock e_t
al., 1984). The distribution of values is not normal,
therefore percentiles were required to identify the level
at which a value could be considered abnormal. This means
that prenatal diagnosis can only be performed accurately
in individuals with a 1 in 4 risk of carrying a CF fetus.
The level of the intestinal isoenzyme of alkaline
phosphatase (I-ALP) in amniotic fluid was also observed to
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be greatly reduced where the fetus had CF (Brock, 1985).
In routine diagnosis of CF four enzymes (GGTP, APM,
I-ALP and a-g 1 ucosidase) are measured, optimally, at a
gestation of 18 weeks.
In general there is concordance between peptidase,
I-ALP and disaccharidase activities in amniotic fluid.
However, Brock and Clarke (1987) have reported an unusual
enzyme pattern in 7 out of a series of 260 high risk
samples. In all cases a low value of GGTP accompanied a
normal APM, a high normal I-ALP and a marginal
a-g 1 ucosidase. All 7 pregnancies went to term and resulted
in 5 live-born CF and 2 normal infants.
The low levels of microvillar enzymes observed in the
majority of amniotic fluids where the fetus has CF are
most likely due to a mechanical obstruction of fetal
meconium (Kleijer et a 1 ., 1985). This explanation does not
account for the 7 anomalous samples. The levels of the
four enzymes have been measured in fetal meconium from 19
putative CF fetuses and 32 without CF all at a gestation
from 18-21 weeks (Brock and Barron, 1986). In CF fetuses
the levels of enzymes were significantly elevated. By
comparing the ratios of enzymes in fetal meconium with the
levels in amniotic fluid GGTP, APM and a-glucosidase are
very similar at approximately 100:1, whilst I-ALP has a
ratio of 1000:1. This may explain why I-ALP does not
always correlate with the other three enzymes. The
apparently normal level of I-ALP in a small number of CF
amniotic fluids may be due to an intrinsic elevation of
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the enzyme level present in the fetal meconium.
Extensive data has now been published on the
diagnostic potential of peptidases (Brock et a 1., 1984;
Brock, 1985; Muller et a 1 ., 1985; Aitken et a 1 ., 1985),
isoenzymes of ALP (Brock, 1985; Brock et a 1 ., 1985 ; Muller
et a 1 ., 1985 ) and disaccharidases (Kleijer et a 1 ., 1985;
Szabo et a 1 ., 1985). A prospective series of 200 cases at
1 in 4 risk of CF indicates an accuracy of 98% (Boue £t
ajk, 1986).
1.3.2. CF-linked DNA Probes.
The identification of CF-linked DNA probes has
enabled prenatal diagnosis for CF to be undertaken using
fetal material obtained by chorionic villus sampling at a
gestation of 8-10 weeks (Farrall et a 1 ., 1986). These
linked probes are only useful for prenatal diagnosis in
families with at least one CF child. DNA must be available
from an affected child, in the family being tested, to
establish phase relationships between the probes and the
CF gene. With the use of several linked probes; metD, metH
(White et a 1 ., 1985), J3.ll (Wainwright et a 1 ., 1985 ), 7c22
(Scambler et al., 1986a) and B79A ( Estivill et a 1., 1986 ),
the majority of families investigated are fully
informative and all affected offspring can be identified.
Data from a collaborative study of 211 families (Beaudet
et a 1 ., 1986 ) showed that >95% of these families showed
linkage to chromosome 7q markers. In some families, where
all the markers on one parent's chromosomes are
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homozygous, only the the other parent's affected
chromosome can be identified. In these partly informative
families 50% of the offspring will have a normal
phenotype. The remaining 50% will have a 50% chance of
being affected with CF. In these cases the families may be
advised to opt for microvillar enzyme testing.
The DNA probes have been used to confirm the
diagnosis of fetuses terminated on microvillar enzyme
results (Curtis et a 1.) In some families the index case
for CF may have died and no DNA is available, but material
is available from a fetus terminated on the basis of
microvillar enzyme results. In these cases prenatal
diagnosis may be possible using the fetus as the index
case. The false positive rate for microvillar enzymes is
very low (<5%). In these few cases an error in the phase
relationships betwen DNA markers and the CF gene will
result in half the diagnoses being wrong and a quarter
will lead to the birth of an affected child (Curtis ejt
aj. ). However, in the remaining 95% of cases the diagnosis
will be correct. If there are other non-CF siblings in the
family then it may be possible to establish the phase
relationships and confirm the fetal CF diagnosis.
Prenatal diagnosis is now widely available using DNA
markers. However, it is only available to families where




Prenatal testing for CF can only be undertaken in
families where there is already a CF child. Therefore,
there are still many children born with CF who could not
be identified by any of the available prenatal tests. For
these children early diagnosis and treatment may be important,
and improve their overall prognosis, although no hard
evidence is available on this observation.
For many years the only method of neonatal screening
available involved the measurement of albumin in meconium
of newborn infants (Harries, 1978; Antonowicz and
Schwachman, 1979). A raised level of albumin indicated a
reduced level of pancreatic enzymes.
More recently measurement of immunoreactive trypsin
(IRT) at 5 days after birth using whole blood spots has
been used (Crossley et a 1 ., 1979; Heeley et a 1 ., 1982).
This method, particularly if followed by a repeat test two
weeks later, is a very efficient screening test. Infants
born with meconium ileus tend to have normal levels of
immunoreactive trypsin in their serum (Duhamel et a 1.,
1984), however, these children are considered for possible
CF diagnosis because of this disorder. Individuals with
repeated high levels of IRT have their diagnosis confirmed
by sweat testing, usually at 3-6 weeks after birth. IRT
screening is very successful in early diagnosis of CF.
However, it is not used in routine screening as intended,
mainly because of the expense, but is reserved for infants
with a family history of CF or showing clinical symptoms.
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The CF-linked DNA probes may be of use in
confirmation of diagnosis, especially in siblings of CF
children where the IRT and/or sweat test results are
margina1.
1.5. Heterozygote Detection.
For many years many laboratories have been searching
for a heterozygote detection test for CF. The research has
been characterised by a large number of experiments which
have revealed opposite results in different laboratories.
Requirement for heterozygote detection can be divided
into two situations either for testing of individuals in
families where the CF gene has already been identified or
else in the general population. In the former case the aim
would be to exclude heterozygosity of individuals whose
risk of heterozygote status is either greater than in the
general population (siblings of affected individuals) or
those who wish to have children, but whose partner is
either a confirmed heterozygote (having already borne a
child with CF) or homozygous for CF.
If a heterozygote test is to be used to segregate out
from a large general population then the test must use an




Many abnormalities have been described in CF cells
(Mangos and Boyd, 1984). However, the majority of reported
observations have not included any data on heterozygous
individuals.
Several heterozygote tests using cultured skin
fibroblasts have been described. Shapiro et a 1 . ( 1979)
observed that the measurement of mitochondrial NADH
dehydrogenase over a pH profile provided an indication of
genotype. In CF patients highest activity was at pH 8.6,in
heterozygotes at pH 8.3 and in normal controls at pH 8.0.
Sanguinetti-Briceno and Brock (1982) have been unable to
confirm these observations. Measurement of this enzyme in
white blood cells and cultured lymphocytes also showed no
effect of pH.
Breslow et a 1 . ( 1978) demonstrated that when
fibroblasts were exposed to low concentrations of
dexamethasone, heterozygote cells survived for an
intermediate time when compared with CF homozygotes and
normals. However, at all concentrations of dexamethasone a
significant overlap was observed. By simultaneously
measuring sodium transport in the presence of ouabain and
the dexamethasone resistance Breslow et a 1. (1981) could
identify all three genotypes correctly. These observations
could not be repeated and were withdrawn (Breslow and
McPherson, 1981).
Reduced p-adrenergic responses have been demonstrated
in granulocytes (Gallant et a 1., 1981) and in lymphocytes,
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granulocytes and in the cardiovascular system of CF
patients (Davis et a 1., 1983 ). In leukocytes this defect
appeared at an intermediate level in CF heterozygotes,
suggesting an inherited defect and not a secondary effect
of disease. The basal levels of cyclic adenosine
monophosphate (cAMP) were the same in both CF homozygote,
heterozygote and normal lymphocytes and granulocytes, but
- 8the levels in response to isoproterenol (10 M) were
significantly reduced in both cells, although there was
overlap between all three groups. It was
suggested that these observations indicated that the
p-adrenergic receptors are normal in CF granulocytes and
lymphocytes,but there is an abnormal inheritable
defect in the receptor-cyclase coupling of the
B-adrenergic system.
1.5.2. Bioassays of CF factors.
Many abnormalities have been described, in bioassay
systems, which are caused by a substance present in the
serum or secretions of CF homozygotes and heterozygotes.
These substances have become collectively known as
CF-Factors.
The effect of sera and other biological fluids on the
sodium-dependant glucose transport system has been
studied. Several laboratories (Araki et a 1 ., 1975 ; Gilmore
et a 1 ., 1978; Tucker et a 1 ., 1979 ) reported a bioassay
using rat jejunum which identified a diminished short
circuit current with CF homozygote and heterozygote sera,
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in the presence of glucose, compared with control sera.
These observations showed a large overlap in all the
studies. When rat brush-border vesicles were substituted
for jejunum no differences were observed (Will et a 1.,
1979), suggesting that the sodium transport inhibition
detected may be tissue specific.
Rabbit tracheal assay and oyster gill assay have been
the main tissues used in the assay of substances in CF
homozygote and heterozygote sera which inhibit the
motility of cilia. Fresh water mussel (Bes1ey et a 1.,
1969 ) and mouse sperm (Pivetta et a 1 ., 1979) have also
shown similar inhibition.
Spock et a 1 . ( 1967 ) were the first to show that CF
homozygote and heterozygote sera contained substances
which inhibited the motility of rabbit tracheal cilia. The
material was shown to be heat labile, non-dialysable and
precipitated with the euglobulin fraction of serum. Later
this was identified as a substance with a molecular weight
(MW) of 1000-10000 daltons which was associated with IgG
(Conod et a 1 ., 1977 ). Others have confirmed that CF
homozygote and heterozygote sera contain a ciliary
dyskinesia factor bound to IgG (Wilson and Fudenerg,
1977a). This factor could be isolated from IgG by
protein-A sepharose chromatography (which bound IgG and
the factor) then eluting at an acidic pH (Wilson and
Fudenberg, 1978). This acid-stable protein of MW 4000-6000
was also found in other biological fluids and could
produce ciliary dyskinesia without IgG.
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Initial work indicated that ciliary dyskinesia was
specific to CF homozygote and heterozygote fluids (Spock
et a 1. , 1967 ). Later it was shown that sera from patients
with asthma, pulmonary and autoimmune diseases could also
cause ciliary dyskinesia in the rabbit tracheal assay
(Conover et a 1 ., 1976). The factor in asthmatic patients'
sera could be differentiated from the 4000-6000 MW factor
in CF by chromatography on DEAE-ce 11 u1ose followed by
Sephadex G200 gel filtration (Wilson and Fudenberg,
1977b).
Phytohaemagg1utinin stimulated lymphocytes,
lymphoblastoid cell lines and fibroblasts from CF
homozygotes and heterozygotes were shown to secrete a
1000-10000 MW substance that requires IgG to cause ciliary
dyskinesia in the rabbit tracheal assay (Conover et al.,
1976) Three low MW substances were also secreted from
lymphocytes, lymphoblastoid cell lines and
monocyte/macrophages which did not require IgG (Wilson and
Fudenberg, 1978). Purification and culture of
sub-populations of leukocytes showed that ciliary
dyskinesia factors were secreted by T-lymphocytes and
monocytes, but not by B-lymphocytes or neutrophils (Wilson
and Bahm, 1980).
A glycopeptide of MW 5000, which caused ciliary
dyskinesia, was purified by Blitzer and Shapira (1982a).
Monoclonal antibodies were produced against this factor
Blitzer and Shapira, 1982b), but none showed any
immunological differences when tested against CF
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homozygote, heterozygote or control sera.
A mucociliary factor was found in the sera from CF
homozygotes and heterozygotes, but not in sera from
controls including sera from bronchial asthmatics, by the
oyster gill assay (Bowman et a 1 ., 1969).This substance was
heat labile, cationic and associated with IgG (Bowman £t
a 1 ., 1970). A substance was purified from CF homozygote
and heterozygote plasma which could be dissociated from
IgG with 6M guanidinium chloride (Carson and Bowman,
1982). IgG was not required for ciliary diskinesia in the
oyster gill assay. A factor was also found in fibroblast
medium (Bowman et a 1 . , 1973b) and urine (Bowman et a 1.,
1977) from CF homozygotes and heterozygotes. The factor
present in urine has been purified and has a MW 4000-13000
(McNeely et a 1 ., 1982).
Several of the body fluids which have caused inhibition
of ciliary motility have also induced mucus production in
biological assays. Isolated acini from the rat
submandibular gland have also been observed to increase
secretion of glycoproteins in the presence of CF
homozygote and heterozygote sera (Fleming and Sturgess,
1981; Macpherson et a 1 ., 1983).
The difficulties encountered in repetition of results
in all the CF factor bioassays has led to a great deal of




A lectin-like substance found in CF homozygote and
heterozygote serum has been assayed by a haemagg1utination
assay using mouse erythrocytes (Lieberman et a 1 ., 1979 ).
The lectin of MW 3,500-10,000 was bound to IgM but could
be isolated on a fructose-sepharose column (Nordstrom ^t
a 1 . , 1980). The assay was very variable using whole serum,
but modification of the assay using the IgM fraction of
sera (isolated by gel filtration) was more reproducible
(Lieberman et a 1 ., 1984). In a 'blind' assay 95% of CF
homozygotes, 89% of heterozygotes and 5% of controls were
identified as having an elevated lectin titre. No other
laboratories have reported repetition of this assay.
1.5.4. Arginine esterases.
The cascade enzymes involved in coagulation,
ka11ikrein-kinin system and fibrinolysis have been studied in
relation to CF. An excess or deficiency of enzyme activity
was thought a very likely candidate for the defect in CF.
Arginine esterase activity was shown to be diminished
in ch1oroform-e11agic acid treated plasma in CF
homozygotes compared with normals (Rao and Nadler, 1974).
This observation was confirmed by some investigators
(Coburn et a 1 ., 1974; Chan et a 1 ., 1977), but not by
others (Lieberman, 1974; Goldsmith et a 1 ., 1977 ). Further
work demonstrated a deficiency using the artificial
substrate MUGB (Walsh-Platt et a 1 . , 1979). This work has
not been repeated, and in view of the substrate being
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shown to measure esterolytic activity of serum proteins
the results probably reflect the generally increased level
of proteins in CF serum.
1.5.5. Protease inhibitors.
Many workers have studied the protease inhibitor
a2~macrog1obu 1 in (a2M). Several abnormalities have been
reported but most of these have been contradicted in other
reports.
Shapira et a 1 . ( 1976a; 1976b) observed normal levels of
a2M in the serum and plasma of CF patients, obligate
heterozygotes and normal individuals. However, these
studies showed absence of the a2M-protease complex in CF
homozygotes with an intermediate level in heterozygotes.
The a2M seemed to be antigenically similar in all three
genotypes. There appeared to be a 40% reduction of sialic
acid content and defective binding to Concanavalin A
(Con-A) and wheat germ agglutinin, suggesting a defect in
the carbohydrate residues of the protein (Ben-Yoseph jet
aj., 1979).
In contrast other studies have shown normal trypsin
binding (Parsons and Romeo, 1980), normal 2-dimensiona1
electrophoresis patterns (Comings et a 1 ., 1980), increased
trypsin binding (Schidlow and Kueppers, 1980) and
increased Con-A binding (Shapira and Menendez, 1980) in CF
homozygotes and heterozygotes.
A monoclonal antibody which recognised a structural
variation in a2M has been described (Eager and Kennet,
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1984). The antibody showed significantly reduced binding
to purified a£M from 4/5 CF homozygotes,3/4 obligate
heterozygotes compared with 13 normal controls. They
hypothesised that the reason for this was either a
decreased number of antigenic determinants on a^M or an
altered antigenic site.
a^-antitrypsin, another potent protease inhibitor,
has been studied extensively (Talamo et a 1 ., 1976 ).
However, no genetic, quantitative or functional
abnormalities have been identified, although increased
levels are observed in CF homozygotes with increased age
and progression of chronic pulmonary disease.
1.5.6. Hydrolases.
Hosli and Vogt (1979b) reported that heat inactivation
of plasma a-mannosidase and acid phosphatase could be used
to differentiate all three CF genotypes. The two enzymes
retained nearly all their activity in normals (80-100%),
40-60% in heterozygotes and 0-10% in CF homozygotes. There
was no overlap between the groups. A "blind" trial
reported by Katznelson et a 1 . ( 1983) showed that 45 plasma
samples collected in Israel and tested by Hosli and
colleagues were all correctly genotyped. Despite the
apparent simplicity of this assay other laboratories have
failed to reproduce these results (Harris et a 1 ., 1979;
Patrick and Ellis, 1979).
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1.5.7. Other Proteins.
One of the most repeatable biochemical methods
reputed to track the CF gene was the identification of an
abnormal doublet band after polyacry1 amide gel isoelectric
focusing of serum from CF homozygotes and heterozygotes
(Wilson et a 1., 1973 ). This observation was the starting
point for the work described in this thesis and is
explained in detail in Chapter 2.
1.5.8. DNA Studies.
DNA-linkage studies on the siblings of CF homozygotes
has enabled their heterozygous status to be determined. In
some cases it has been possible to use linkage analysis to
exclude heterozygosity in individuals who are at a higher
risk of carrying the CF gene than in the normal
population.
Brock et a 1 .( 1986) have described a case study where
a couple enquired about prenatal diagnosis of CF. The
husband's brother was married to his wife's sister and
they had produced a child with CF. Therefore the couple's
risk of having a CF child was 1/16, which is low for
microvillar enzyme testing. By DNA typing the extended
family it was possible to show that the 'at risk' wife was
not a carrier of the CF gene, whilst the husband had a 50%
risk. Even allowing for maximum recombination of 3% their
risk of having a CF child was now reduced to 1/135. Even
though this was an unusual family it illustrated that in
some cases it is possible to identify heterozygote status
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in individuals who are not siblings of CF homozygotes or
parents of a CF child.
In a recent report Estivill et a 1 . ( 1987 ) have
described 2 new DNA probes (XV-2c and CS.7) which were
derived from cosmid libraries constructed from mouse/human
cell lines. These cell lines were produced using
chromosome-mediated gene transfer (Scambler et a 1 ., 1986b)
and were shown to contain the markers most closely linked
to CF.
Probe XV-2c detects an RFLP at a frequency of 0.47
for allele 1 (2 .1k b) and 0.53 for allele 2 (1.4 k b) in Taql
digests. Probe CS.7 detects an RFLP at a frequency of 0.56
for allele 1 (0.67kb) and 0.44 for allele 2 (0.47kb) in
Hhal digests. No recombination with CF was observed in 6
informative families showing crossover between CF and
J3.ll or 7c22 and/or B79A. The order of loci is thus
7qter-J.311-(CF/CS.7/XV-2c)-met-7c22-B79a-7cen.
In 195/213 chromosomes studied the CF mutation was
associated with probe XV-2c allele 1 and in 70/71
chromosomes with probe CS.7 allele 2. This suggested that
the CF was closer to CS.7 than to XV-2c. One family
studied, in which the CF chromosome was associated with
the probe CS.7 allele 1, was the only crossover family in
which XV-2c, met and 7c22 recombined with CF. The reason
for this anomalous result was not clear.
A weak non-random allelic association was
demonstrated in J3.11/CF and met/CF haplotypes (Beaudet ejt
al., 1986). The markers CS.7 and XV-2c showed strong
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linkage disequilibrium both for normal and CF chromosomes.
In the families studied (excluding the CS.7 allele 1
associated family) 94% of CF chromosomes were XV-2c allele
1 and CS.7 allele 2, wheras only 34% of normal chromosomes
showed this haplotype. Therefore, it was concluded, that
an individual in a normal population who did not have this
haplotype would be at a greatly reduced risk of carrying
the CF gene compared with the the risk of 1/20 in the
total population. Alternatively an individual who was
homozygous for the haplotype would have an increased risk
of 1/7 of being a carrier.
The assesment of risk for carrier status is
particularly important in families where one partner
either has a high prior risk or is known to be a carrier
of the CF gene. In these couples, a low risk of carrier
status will reduce risk of having a CF child to levels




The work described in this thesis was part of a large
research programme undertaken by the Cystic Fibrosis
Research Trust/Medical Research Council Research Group on
Cystic Fibrosis, in Edinburgh.
The purpose of this project was to assess the
potential clinical usefulness of reported biochemical
methods of CF heterozygote detection.
Wilson et a 1 . ( 1973 ) had reported an abnormal doublet
band observed, after isoelectric focusing (IEF), in CF
homozygote and heterozygote serum. In this laboratory,
work had started on the production of a polyclonal
antiserum against the portion of gel containing the
doublet band (Manson and Brock, 1980). A limited quantity
of antiserum was available which showed apparent
quantitative differences in serum, dependent on the CF
genotype. However, the titre and quality of this antiserum
was extremely variable and therefore, no large scale serum
testing could be undertaken.
The aims were; a) to repeat the observations made by
Wilson et a 1 . ( 1973), b) to produce a sufficient quantity
of a consistent quality, high titre, antiserum to test a
large number of serum samples and confirm the potential of
using this assay in detecting CF heterozygosity and then
c) to produce monoclonal antibodies against the protein
identified by the polyclonal antiserum.
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Once specific monoclonal antibodies were identified
and a sensitive assay system devised it was hoped that
measurement of the protein in serum would be simple,
highly reproducible and suitable for use in CF






Isoelectric focusing (IEF) is electrophoresis in a
continuous stable pH gradient. The separation depends on
the isoelectric point (pi) of the protein. Once a protein
has reached its pi position it has no net charge and
therefore can migrate no further. In this process there is
a concentrating effect which produces sharp, stable
protein zones.
The production of a stable linear pH gradient depends
on the ampholytes. They must have a high buffering
capacity to overcome any influence of the proteins
themselves. They must also have an even conductance,
especially at their own pi's, to maintain a flow of
current through the system. These carrier ampholytes
comprise many isomers and homologues of aliphatic
polyamino-polycarboxylic acids with different pi's
depending on the pH range required. The ampholyte pH
gradient is formed when an electric field is applied. The
molecules with lowest pi (highest negative net charge)
will migrate towards the anode. When they reach a position
where the net charge is zero, they will stop migrating,
adjacent to the anode, and because of their high buffering
capacity, these molecule will impart to the surrounding
solution a pH equal to its own pi. All the carrier
ampholyte molecules arrange themselves in series between
the anode and cathode electrodes, in increasing order of
-25- Chapter 3
pi, and thus produce a pH gradient increasing from anode
to cathode.
The pH gradient formed can be influenced by addition
of substances, such as 4M Urea, which can alter the pi of
proteins by several points of a pH unit. Urea is used as
a solubi lising and dissociating agent. High concentrations
disrupt the hydrophobic bonds of proteins and cause them
to unfold. Therefore the pi of a protein in the presence
of urea cannot be correlated with that obtained in an
aqueous environment.
The use of high power increases the speed of
formation of the gradient and therefore the separation
time. Adequate cooling is necessary and a temperature of
4°C is recommended.
3.1.2. IEF of serum samples.
In 1973 Wilson et a 1. demonstrated, by IEF, a band in
serum at pi 5.48 which was detected in control and CF
heterozygotes, but not in CF homozygotes, whereas a band
at pi 8.41 was demonstrated in CF homozygotes and
heterozygotes but not in normal controls. Later studies
observed the pi 5.48 band present in more than half of all
serum samples tested. This was susequently identified as
an a^M fragment generated by proteolytic cleavage. (Wilson
& Fudenberg, 1976). The detection of the pi 8.41 band in
CF homozygotes and heterozygotes and occasional normals
was reported by several laboratories, (Scho1ey et a 1.,
1978; Nevin etal., 1981; Hallinan et a!., 1981; Brock et
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a 1., 1982; Grataroli et a 1., 1984 ; Super and Swindlehurst,
1984; Jamieson et a 1., 1985 and Getliffe et a 1 ., 1986)
whilst other workers failed, (Smith et a 1 ., 1976 ; Thomas
et a 1 ., 1977 ). Modifications of the IEF technique showed
this band as a doublet at pi 8.46 _+ 0.05. Wilson laid out
strict methods of collection, storage and processing of
sera for correct identification of this abnormal band,





Blood was collected from 23 CF homozygotes, 22 CF
heterozygotes and 16 healthy controls, into glass tubes
(Seward). The samples were immediately cooled to 4°C and
allowed to clot for 4-6 hr before centrifugation at 4°C
for 10 min at 600g. The serum was aliquotted into plastic
tubes and stored frozen at -70°C until required. Each
aliquot was electrofocused immediately after thawing and
the excess discarded.
IgG levels in serum samples were quantitated in the
Clinical chemistry laboratory, Western General Hospital,
Edinburgh.
3.2.2. Preparation of gel and running conditions for IEF.
IEF was performed using the LKB Multiphor apparatus.
2mm thick gels were used with acrylamide / bisacrylamide
composition T = 5%, C = 3%.
Each gel contained :
9ml acrylamide / bisacrylamide
(33g/1g in 100ml of distilled water)
50ml of urea (freshly prepared)
(12.5g made up to 50ml in distilled water)
2.9ml Ampholine pH 3.5-10 (LKB)
0.1ml Ampholine pH 2.5-4 (LKB)
0.2ml of 10% ammonium persulphate
0.3ml of 5% TEMED (N,N,N,N-tetramethy1 ethylenediamine)
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After polymerisation at room temperature (RT) for 1 hr
the gel was placed at 4°C overnight. Before
e 1 ectrofocusing of samples, the gel was prefocused. The
electrofocusing strips were soaked in electrode solutions,
cathode: 5% v/v TEMED ; anode: 3% v/v phosphoric acid, and
placed on the gel in contact with the electrodes. The gel
was prefocused for 1 hr at 40mA on a cooling plate at
4°C. The strips used for prefocusing were replaced with
fresh soaked strips before the samples were applied to
5x10mm pads of Whatman 3MM filter paper 10mm from the
anode electrode strip. Undiluted serum samples, each
containing 300pg of IgG , were applied together with known
positive and negative controls. IEF was performed at
constant power 38W, with maximum voltage 1200V for 1.5
hr at 4°C.
3.2.3. Gel staining.
The gel was fixed and stained in a solution
containing 45g trichloracetic acid, 13.5g sulphosalicylic
acid and 0.45g Coomassie Blue in 135ml of methanol and
280ml of distilled water. The gel was placed in this stain
in a water bath at a temperature of 80°C, in a fume
cupboard, and allowed to cool to RT, before being washed
in distilled water to remove excess stain. Destaining was
achieved by repeated washing in ethano 1/disti 1 led
water/acetic acid (6/13/1 v/v). The presence or absence of
the doublet band could be ascertained by observing the
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gels through an orange filter and comparing with the known
positive and negative controls. The protein pattern of IEF
of normal, CF heterozygote and CF homozygote serum is
shown in Fig 3.1. The position of the doublet band is
indicated by the two bars.
1 2 3
Fig.3.1. IEF of serum samples.
Track (1) CF heterozygote; (2) healthy control; (3) CF




3.3.1. Qualitative analysis of CFP.
Three "trained" observers scored the serum samples
(without being aware of donor status) by comparison with
one positive and one negative control on each gel. The gel
was scored with a value of 2 for a definite, 1 for a
doubtful and 0 for an absent doublet band. Each sample was
run on a minimum of two seperate gels allowing for six
observations. Samples scored variably by the different
observers were run up to 8 times
The average score for each sample was derived by
summing the individual scores and dividing by the number
of observations. Samples which were scored variably by
different observers were run repeatedly until concordance
was achieved. Since the observers were not aware of the
source of the samples it is unlikely that this introduced
any systematic bias towards definite, doubtful or absent
scores. An average score of greater than 1 indicated a
positive result. 19 out of 23 CF homozygotes, 16 out of 22
CF heterozygotes and 3 out of 16 controls showed such a
score. The mean and standard deviations of the average
scores are shown in Table 3.1. By using the Student
t-test, the mean values of CF homozygotes and CF
heterozygotes showed no significant difference, whilst the
differences between CF homozygotes and controls and
between CF heterozygotes and controls were highly
significant (p<0.001).
Table 3.1. Scoring of IEF samples.
Group Number Mean and*SD.
Controls 16 0.45 _+ 0.48
CF heterozygotes 22 1.22 + 0.44
CF homozygotes 23 1.45 _+ 0.50
*
SD., standard deviation from the mean.
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3.4. Discussion.
3.4.1. CFP analysis in other laboratories.
The results of this study indicate that this method is
not reliable enough to distinguish the presence of the CF
gene in the sample tested. The majority of samples are
correctly identified but the misdiagnosis of 19% of the
normal controls, 27% of CF heterozygotes and 17% of the CF
homozygotes is unacceptably high for use of this test as a
heterozygote detection test in a normal population. Several
other laboratories have attempted to identify this protein
by isoelectric focusing with varying degrees of success.
These results are summarised in Table 3.2. The
identification of the protein in CF homozygotes ranges from
26% to 100%, CF heterozygotes from 13% to 90% and normals
from 0 to 23%. All these laboratories followed the Wilson
method of blood collection in the first instance. Hallinan
et a 1. (1981) were the least successful and despite
following Wilson's IEF method meticulously only identified
26% of CF homozygotes and 13% of CF heterozygotes. They
then pre-treated samples in various manners including
pre-incubation at 56°C, 37°C and 4°C, in the presence and
absence of protease inhibitors, EDTA and hydrochloric acid
and also collected blood into plastic tubes, and
anticoagulants heparin, citrate and EDTA. All these
modifications had no improving effect on their detection
of CFP.
Wilson et a 1 . ( 1984) compared the detection of CFP in





Wi1 son et a 1. 1975 serum 97 93 9
Scholey et al. 1978 serum 70 ND 0
Nevin et a 1. 1981 serum 90 83 8
Ha 11 inan et a 1 . 1981 serum 26 13 8
Brock et al. 1982 serum 83 73 19
Wi 1 son et a 1. 1984 serum 100 86 12
Wi1 son et a 1. 1984 heparinised 100 90 4
p 1 asma
Grataroli et al. 1984 serum 71 71 20
Subset of serum samples 75 78 40
of which heparinised plasma
was also collected •
heparinised 92 67 20
plasma
Super & Swindlehurst serum 92 88 8
1984
Jamieson et al . 1985 serum 79 44 23
Getliffe et al . 1986 serum 91 88 8
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serum and heparinised plasma. Despite initially insisting
that the method only worked using carefully collected serum
the results are almost identical for the two sets of
samples with slightly increased identification of CF
heterozygotes (4%) and decreased positivity in the normal
controls from 12% in serum to 4% in heparinised plasma.
Grataroli et a 1 . ( 1984) published a smaller series with
similar results. Jamieson et a 1 . ( 1985) collected samples
in the method described by Wilson but then modified the
IEF technique significantly and used Pharmacia ampholytes
which are a different mixture compared with those from
LKB. They claim to have identified CFP by this method, but
were less successful than most others in discriminating
normals from carriers of the CF gene. They further changed
the method by silver staining which identified even more
CFP positive normals. They concluded that CFP was a
"normal serum protein showing quantitative variation
dependant primarily on the CF allele".
Despite the technical difficulties encountered in IEF
of serum to identify CFP, the general consensus is that
there is a protein present in serum which seems to be





4.1.1. Polyclonal antibodies to CFP.
An antiserum to the doublet band defined as CFP
(Wilson et a 1 ., 1977b; 1979 ) was first produced by Manson
and Brock (1980). This antiserum was raised in guinea pigs
by immunising with the excised, pH 8.46, portion of an IEF
gel, previously homogenised in phosphate buffered saline
(PBS). The antiserum produced, after absorption with CFP
negative sera, was suitable for use in rocket
immunoelectrophoresis (RIE) and showed a quantitative
difference between CF homozygotes and CF heterozygotes as
well as between CF heterozygotes and healthy controls,
which appeared negative. Later that year Wilson (1980)
reported an antiserum which was produced in mice. This
antiserum was absorbed with CFP negative sera and then
tested by counterimmunoelectrophoresis (CIE). The
precipitin line for CF heterozygote serum was closer to
the antigen well than for CF homozygote serum, indicating
a lower level of antigen in CF heterozygotes. RIE using
this antiserum showed a quantitative difference similar to
that described by Manson and Brock (Wilson, 1982). The
identity of the antiserum produced by Manson and Brock
compared with that produced by Wilson is unknown.
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4.2. Methods.
4.2.1. Preparation of IEF gel as immunoqen.
6 CFP positive sera from CF homozygotes were pooled
and run on IEF gels as described previously. A single
sample lane from each gel was cut out and stained
according to the protocol described. The doublet band was
identified and the portion of unstained gel, pH 8.4-8.5,
was excised and homogenised in 1ml of PBS for each gram of
gel. Homogenisation, although difficult, was achieved by
repeated passage through diminishing sizes of needle,
using a glass syringe, until the mixture could pass
through a 23 gauge needle.
4.2.2. Immunisation of guinea pigs and antisera testing.
The immunisation schedule was as described by Manson
and Brock (1980), using the same inbred colony of guinea
pigs. Initial immunisation was with 1ml of homogenate
intramuscu1arly in several sites. At four week intervals
2ml of homogenate was injected intraperitonea1ly and from
the sixth week the guinea pigs were bled weekly by cardiac
puncture. The blood was clotted overnight at 4°C and the
serum removed. Before testing, small volumes of the
antiserum were absorbed with increasing volumes of a pool
of 6 CFP negative serum samples. The antiserum was then
tested, at varying concentrations from 20%-50% by RIE,
using a pool of 6 CF homozygotes as the positive control
and a pool of 6 normals as the negative control. The
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buffer system used was as described by Laurell and McKay
(1981) containing 75mM sodium barbitone, 16mM barbitone
and 1.4mM calcium lactate (pH 8.6). The 1% agarose gels
were run overnight at 1 V/cm with cooling. All antisera
showing a positive reaction with CF homozygote serum and a
negative result with normal serum were pooled, absorbed
and retested against a panel of serum samples. This
antiserum was referred to as anti-IEF.
A large series of sera were tested against anti-IEF
(Bullock et a 1., 1982 ). In this series the antigen level
was quantitated by measuring the area under the precipitin
peak. The sera were tested against two batches of antisera
(AS60 and AS82/83) produced at an interval of more than a
year.
These same batches of antisera were also used as the
basis of an immunoradiometric assay (IRMA). Test sera of
different dilutions, up to 1/50 in 0.05M phosphate buffer
pH 7.5, were coated onto plastic tubes and incubated
overnight at RT. The tubes were then blocked with PBS
containing 5% horse serum to saturate binding sites.
Guinea pig antisera were diluted up to 1/20,000 in PBS and
incubated in the coated tubes overnight. In order to
detect the binding of the guinea pig Ig to antigen, all
125
tubes were then incubated with an equal quantity of I
Protein A (35,000cpm) (Amersham). The bound radioactivity
was expressed as a percentage of the total counts added to
each tube.
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4.2.3. Immunodepletion of anti-IEF rockets.
Serum samples were run by RIE through a high
concentration of several commercially available polyclonal
antisera before reacting with anti-IEF, to establish that
the antiserum was not against a common known protein. The
principle of this technique is illustrated schematically
in Fig 4.1.
CF homozygote serum was also tested for depletion
with Protein A Sepharose CL-4B. lOOpl of a 10% w/v mixture
of Sepharose CL-4B was incubated with 20pl of serum, for 1
hr, to remove the proteins which bind to protein A. IgG is
the main serum protein to bind, but IgA and IgM will bind
to a lesser extent. lOOpl of Protein A sepharose will bind
approximately lmg of IgG, which is approximately double
the maximum amount present in 20pl of CF serum (CF
homozygote range : 13.85 - 21.81 mg IgG/ml serum,
Schwartz, 1966). The serum/sepharose mixture was
centrifuged and the supernatant run by RIE against
anti-IEF.
4.2.4. Gel filtration of serum.
The molecular weight of the protein detected by
anti-IEF in serum was estimated by Sephacryl S300
(Pharmacia) gel filtration. Sephacryl S300 is a
covalently cross-linked dextran with N,N-methylene
bisacrylamide giving a rigid gel with a controlled range
of pore sizes and a fractionation range for proteins of
MW 1x 104-1 .5x106.
Fig.4.1. Immunodeplet ion of the anti-IEF rocket produced
from CF serum, using commercially available
polyclonal antisera.
A commercial antisera is used to deplete
specific proteins from a CF serum pool. Any
antiserum which cross-reacted with the protein
detected by anti-IEF would show reduction or

















A 400ml column with a bed length of 90 cm was
equilibrated in PBS at a flow rate of lOml/hr. The
column was calibrated with protein standards in the same
buffer and at the same flow rate as column
equilibration. 5 ml of CF serum pool was fractionated on
this column. 5 ml fractions were collected and tested
against anti-IEF by RIE to determine those which were
positive. A normal serum pool was fractionated under the
same conditions.
4.2.5. Polyacrylamide gel electrophoresis.
The pooled positive fractions from a CF serum pool
and the equivalent fractions from normal serum were run
on 15% aery 1 amide-SDS gels using a discontinuous buffer
system (Laemmli, 1970). This technique is characterised
by the use of a stacking gel to concentrate the sample
before electrophoretic separation on the resolving gel.
The electrode buffer used contained 0.025M Tris,
0.192M glycine and 0.05% SDS (w/v) with the pH adjusted
to 8.3. The resolving gel contained 30ml of acrylamide
solution (30g acrylamide, 0.8g
N,N'methy1enebisacry1 amide to a final volume of 100ml in
distilled water), 30ml of Tris-SDS, pH 8.8, (0.75M
Tris,0.4% (w/v) SDS), 15pl of TEMED and 3ml of 1% (w/v)
ammonium persulphate. The solution was mixed gently by
swirling and immediately poured into an LKB 2001
Vertical Electrophoresis Unit to a height of 12cm. The
solution was overlayed with butanol and left to
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polymerise for 1 hr at RT. The overlay was poured off
and the gel surface rinsed with distilled water to
remove the butanol. Before preparing the stacking gel
the distilled water was removed and the polymerised
surface blotted dry with filter paper to remove any
liquid which would inhibit polymerisation at the
resolving gel interface. The stacking gel contained 2ml
of the same acrylamide solution, 10ml of Tris-SDS pH 6.8
(0.25M Tris, 0.4% (w/v) SDS), 8ml of distilled water,
lOpl of TEMED, and 1ml of 1% (w/v) ammonium
persulphate solution. The solutions were mixed by
swirling and poured into the electrophoresis unit over
the resolving gel. A comb, which forms the sample wells,
was inserted into the stacking gel and left to
polymerise for 1 hr. Before sample application the comb
was removed and the wells filled with electrode buffer.
The samples to be e 1 ectrophoresed were mixed with an
equal volume of sample buffer (0.0625M Tris, 2% (w/v)
SDS, 10ml of glycerol, 5ml of 2-mercaptoethanol and
0.1ml of 1% bromophenol blue made up to 100ml with
distilled water) and applied to the gel along with
standard molecular weight markers. The gels were run at
a constant current of 100mA, for approximately 5 hr,
at a temperature of 10°C until the bromophenol blue
reached the bottom of the gel.
The gel was removed from the electrophoresis unit
and immediately placed in a protein stain. The stain
consisted of 1.25% (w/v) Kenacid blue, 45% (v/v) ethanol
-39- Chapter 4
and 5% (v/v) acetic acid in distilled water. The gels
were stained overnight at RT. Destaining was
accomplished by repeated washing in a solution
containing 5% ethanol and 1% acetic acid in distilled
water.
4.2.6. Silver staining.
Silver-staining of proteins, first separated by
electrophoresis, is a much more sensitive technique than
conventional protein staining. The gels which have been
previously stained with Kenacid blue can be further
stained with silver. Gels which are to be si1ver-stained
must not be touched without wearing gloves as
fingerprints stain very strongly. It is also important
to use deionised-disti 11ed water for all steps to
minimise background staining.
Thoroughly destained gels were rinsed in distilled
water to remove destaining solution and then placed in
oxidising solution (1% (w/v) potassium dichromate and
0.02% (v/v) 70% nitric acid in distilled water) for 15
min on an orbital shaker. The gels were then washed
three times with distilled water before being placed in
a silver nitrate solution (0.1% (w/v) in distilled
water) for 30 min. After rinsing once in distilled water
the stain was developed with 3% (w/v) sodium carbonate
and 0.1% (v/v) formaldehyde in distilled water,changing
the developer 3 times. The reaction was stopped with 5%
(v/v) acetic acid when the proteins were dark against a
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still clear background. After 10 min the gels were
transferred to distilled water for storage.
4.2.7. Affinity purification.
The production of a polyclonal antiserum made it
possible to consider purification of the protein by
affinity chromatography. The use of affinity
chromatography for the separation of a protein requires an
antibody which can be bound covalently to a matrix and
still retain its binding affinity for the protein. The
desorbing substances used to remove the protein must be
sufficiently gentle to retain the antigenicity of the
protein. The matrix chosen for coupling of anti-IEF was
CNBr-activated sepharose-4B (Pharmacia). The method used
was that described in the Pharmacia booklet "Affinity
Chromatography Principles and Methods".
The anti-IEF serum was first partially purified by
sodium sulphate precipitation of the Ig fraction. Anti-IEF
was mixed with solid sodium sulphate to a final
concentration of 18% (w/v). The solution was mixed gently
for 1 hr and the precipitate formed centrifuged out at
12000g. The precipitate was washed three times with 18%
sodium sulphate in distilled water to remove
unprecipitated proteins. The precipitate was re-dissolved
in coupling buffer (0.1M sodium carbonate, pH 8.3
containing 0.5M sodium chloride). This was then dialysed
aganst coupling buffer to remove the sodium sulphate.
After dialysis the protein content of the Ig fraction was
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measured using the method described by Lowry et a 1.
(1951).
4.2.8. Measurement of protein.
A reagent for the measurement of protein was prepared
by mixing 10 vols of 2% (w/v) sodium carbonate in 0.1M
sodium hydroxide with 0.1 vol of 1% (w/v) copper sulphate
in distilled water and 0.1 vol of 2% (w/v)
potassium-sodium tartrate. 5pl of protein solution was
made up to 20p1 with distilled water, in a mirotitre
plate, and 0.1ml of the above reagent was added and mixed
vigorously, then allowed to stand for 10 min. 10pl of
Fo 1 in-Cioca 1 teau reagent (diluted with an equal volume of
distilled water) was added and mixed well. The mixture was
incubated at RT for 40 min before reading at a wavelength
of 492nm. A standard curve of bovine serum albumin (BSA)
was run at the same time and the unknown protein values
were calculated from this curve.
4.2.9. Preparation of CNBr-activated sepharose-4B.
The freeze-dried sepharose was swollen for 15 min in
ImM hydrochloric acid and washed on a sintered glass
filter with 200ml of the same solution per gram of dried
gel. 1 gram of gel gives a gel volume of 3.5 ml.
Hydrochloric acid preserves the activity of the active
groups which hydrolyse at a higher pH.
The swollen gel was then washed with 5ml of coupling
buffer per gram of dry gel. The sodium sulphate cut of
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anti-IEF was immediately added at a concentration of 5mg
of protein per ml of gel. The protein solution was then
coupled to the gel by end-over-end mixing for 16 hr at
4°C. The remaining active groups on the sepharose were
blocked by the addition of 0.2M glycine, pH 8.0, and
mixing for 2 hr at RT. The unbound protein was removed by
washing the gel alternately with coupling buffer and 0.1M
acetate buffer pH 4.0 containing 0.5M sodium chloride. The
change in pH is critical in removing non-cova1ently bound
protein. The gel was stored in coupling buffer, at 4°C,
until use.
A 10ml column of CNBr-sepharose-Anti-IEF was
equilibrated with PBS before addition of 1ml of CF serum
pool diluted with 4ml of PBS. The serum sample was
circulated through the column at a flow rate of 5ml per hr
for 16 hr, to remove the protein binding to anti-IEF. The
unbound fraction of serum was collected and the column
washed with PBS.
4.2.10 Desorption of protein from CNBr-sepharose-Anti-IEF.
Desorption of protein was first attempted by using a
change in pH. The 10ml column was washed with 20ml of 0.1M
glycine-HCl buffer pH 2.5 at a flow rate of 2ml per hr.
The pH of the eluent was immediately adjusted to pH 8.5
with solid Tris. The fractions were concentrated to the
original volume of the serum in a Minicon-B concentrator
(Amicon) which dialyses at the same time. The unbound
protein fraction removed with PBS was similarily treated.
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These fractions were tested against anti-IEF by RIE. Both
the unbound fraction and the pH 2.5 eluted fraction were
negative when tested against the antiserum. The same
column was then re-equilibrated in PBS to remove the
acidic pH buffer.
An antigen-antibody complex involves hydrophobic
interactions which can be disrupted by using
polarity-reducing agents such as ethylene glycol.
A 50% (v/v) solution of ethylene glycol pH 8.0 was
used to elute the column at a flow rate of 2ml per hr and
the fractions collected. This was followed by elution with
50% ethylene glycol, pH 11.0. The fractions were
concentrated to the original serum concentration as
described above, and tested against anti-IEF by RIE.
To ascertain whether the column contained any more
protein, further elution using chaotropic agents was
attempted. Chaotropic ions can be used to desorb proteins
by disrupting the structure of water and thus reducing
hydrophobic interactions. These reagents are used at a
neutral pH. The column was washed with 20ml of 1M MgC^ at
a flow rate of 5ml per hr and fractions collected. Then
the column was left in this solution for 2 hr before
further elution with 10ml of 1M MgC^. The process was
repeated with 2M MgC12, 3M MgC12, 1M KSCN, 2M KSCN and 3M
KSCN. The fractions collected were all concentrated to
the original serum volume as above and tested against
anti-IEF by RIE.
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4.2.11 Identification of a tissue source.
Using IEF to produce an immunogen is an expensive,
timeconsuming and technically precise method. The
antiserum produced is weak, requiring large volumes of a
scarce commodity for testing, and was only successfully
identified in a minority of guinea pigs. Therefore the
identification of a tissue source could be useful in
reducing preparation time of immunogen and also enabling
production of a higher titre antiserum.
The protein recognised by anti-IEF was tested for in
the most easily available human materials, saliva, urine,
erythrocytes, mononuclear leucocytes (MNL) and
polymorphonuclear leucocytes (PMNL).
4.2.12. Saliva.
Saliva samples were collected into sterile tubes from
10 CF homozygotes, 6 CF heterozygotes and 6 healthy
controls. These samples were centrifuged at 12000g to
preciptate solid material and then both supernatant and
precipitate, (reconstituted to 10% of the original volume
in PBS and briefly sonicated) were tested against
anti-IEF.
4.2.13. Urine.
Urine samples were collected from the same CF
homozygotes, CF heterozygotes and healthy controls. These
samples were centrifuged at 2000g to remove cells. The
supernatant was either tested neat or concentrated 10-fold
-45- Chapter 4
in a Diaflo Ultrafilter using UM2 membranes (Amicon),
with an exclusion limit of MW 1000 The cell pellet was
reconstituted in 1% of the original volume and briefly
sonicated before testing.
4.2.14. Blood samples.
Blood samples were collected into sodium heparin
tubes from 3 CF homozygotes, 3 CF heterozygotes and 3
healthy controls. The samples were centrifuged at lOOOg
for 10 min and the plasma removed. The plasma was
replaced with an equal volume of RPMI-1640 medium
containing 20 U/ml sodium heparin. The cell suspensions
were diluted with an equal volume of PBS and carefully
layered onto a 1/3 volume of Lymphoprep (Nygaard). This was
then centrifuged at 400g for 30 min and the cell layer at
the miniscus (MNL) was removed using a pasteur pipette.
The remaining supernatant, containing Lymphoprep and
medium, was removed. The cell pellet, containing mainly
erythrocytes and PMNL was returned to the original blood
volume with RPMI-1640 containing 20 U/ml sodium heparin,
mixed with 1/3 volume of 6% (w/v) Dextran 250 in 0.15M
NaCl and the mixture allowed to settle for 30 min at 37°C.
The upper layer containing mainly PMNL was removed. The
erythrocyte pellet was resuspended in PBS to the original
blood volume. The cell suspensions were washed three times
in PBS.
All these samples were tested against a 20%
concentration of anti-IEF using a sample size of 20pl.
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4.2.15. Cell counting.
MNL and PMNL were counted using a haemocytometer
counting chamber. The cells were diluted 1/2 in 1% (w/v)
Crystal violet in 2% (v/v) acetic acid and counted at
100-fold magnification to differentiate between MNL and
PMNL.
MNL and PMNL were pelleted and resuspended at a
o
concentration of 10 cells per ml, freeze-thawed twice and
sonicated. The erythrocytes were checked for leucocyte
contamination and finally diluted to 10% of original
concentration in PBS, freeze-thawed twice and briefly
sonicated.
4.2.16. Leukaemia samples.
Blood was collected into sodium heparin tubes from 14
chronic myeloid leukaemia (CML) patients. Two of whom were
in blast crisis with mainly lymphoid-type cells and two
with myelofibrosis as a complication of the disease.
4.2.17. Granulocyte preparation.
In many cases of leukaemia the blood contained such a
large number of white cells that they could be removed by
simply allowing the red cells to settle. Where this was
not the case the plasma was removed by centrifugation and
an equal volume of RPMI-1640 medium containing 20 U/ml of
sodium heparin was added to the cells. This was mixed with
1/3 volume of 6% dextran-250 in 0.15M NaCl and allowed to
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settle for 30 min at 37°C. The upper layer was removed
and washed three times in PBS. The cells were counted and
resuspended at a concentration of 108cells/ml in PBS.
After freeze-thawing twice, followed by brief sonication,
the cell debris was removed by centrifugation.
20pl of sample (diluted 1/10 in PBS) was tested
against 20% anti-IEF by RIE.
4.2.18. Preparation of guinea pig antiserum to CML
granulocyte lysate (Anti-CML).
An immunogen was prepared from a lysate of CML
O
granulocytes from 6 patients. 10 cells/ml were suspended
in PBS and freeze-thawed twice.The debris was removed by
centrifugation. The protein concentration of the lysate
was 2mg/ml.
200pl of lysate was mixed with an equal volume of
Freund's Complete Adjuvant (FCA) to form an emulsion. This
emulsion was injected intraderma1ly into guinea pigs in
several sites. After 4 weeks the same volume was mixed
with an equal volume of Freund's Incomplete Adjuvant (FIA)
and emulsified before injecting intraperitonea1ly. At
weekly intervals the guinea pigs were bled and the
antiserum tested against a CF homozygote serum pool (as
positive) and a normal serum pool (as negative). The
guinea pigs were boosted, as the antiserum concentration
decreased, with 200pl of CML lysate.
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4.2.19. Comparison of anti-IEF and anti-CML by
Ouchterlony double diffusion.
The identity of the 2 polyclonal antisera was
established by using Ouchterlony double-diffusion.
2Op 1 of CF homozygote serum pool or 20p1 of CML
lysate (1/10 dilution) was allowed to diffuse against 20p1
of each of anti-IEF and anti-CML. The gels were covered
and allowed to diffuse overnight at RT. The gel was washed
repeatedly with shaking, in 0.05% Tween 20 in PBS. The
agarose was then pressed with blotting paper and dried in
an oven. The precipitates were stained in 0.5% Kenacid
Blue in 5/5/1 (v/v) methano1/disti11ed water/acetic acid
for 10 min and destained in repeated changes of
methano1/disti 11ed water/acetic acid as above. When the
background was clear, the gel was dried at RT.
4.2.20. Chromosoma1 assignment.
To observe the chromosomal segregation of the protein
identified by anti-IEF with a human chromosome a series of
somatic cell hybrids were produced from the mouse myeloid
stem-cell line WEHI-TG and cells from four different
myeloid leukaemia patients (van Heyningen et a 1 ., 1985).
Fusion of the leukaemic cells and WEHI-TG was effected at
a ratio of 10 to 1 in the presence of 0.5ml of 25% (v/v)
polyethylene glycol 1500 containing 1,250
haemagglutinating units of B-propriolactone-inactivated
Sendai virus. The fused cells were grown in
hypoxanthine-aminopterin-thymidine (HAT) supplemented
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medium. The mutant myeloma cells cannot grow in HAT
supplemented medium, therefore the hybrid cells can be
selected out. Sub-cloning was by limiting dilution until
reasonable chromosomal stability was achieved. Subclones
were then grown up so that cells from one to three
sequential generations were pelleted for testing against




4.3.1. Antiserum to the IEF doublet band.
In total 128 guinea pigs were immunised with the
homogenate from the IEF doublet band, of which 50 showed a
positive reaction in initial testing. The volume of
antiserum available from each guinea pig was limited to
5ml per bleed and the total was dependent on the
persistence of the antibody reaction, which varied from
animal to animal. Any antibody, produced in this manner,
which showed apparent specificiy for a component in CF
serum was referred to as anti-IEF.
The guinea pig serum in its unabsorbed state showed
several immune reactions against both normal and CF serum
(Fig.4.2a) and on optimum absorption (normally 1 vol of
normal serum to 5 vol of antiserum) showed a monospecific
reaction with CF homozygote serum by RIE (Fig.4.2b). The
optimum antiserum concentration for visualisation of
immunoprecipitin rockets, using 20pl of serum, varied from
batch to batch, but ranged from 20% to 50%.
4.3.2. Quantitive immunoassay of serum samples.
The antiserum produced by Manson and Brock (1980)
showed a positive reaction by RIE with sera from 16 out of
17 CF homozygotes, 8 out of 9 obligate heterozygotes and 1
out of 15 norma 1 subjects. The precipitin peaks were
larger in CF homozygotes than in heterozygotes suggesting
the possibilty of a quantitative biochemical test for CF
a
r
Fig.4.2. RIE of a normal and a CF serum pool against
anti-IEF.
2Op 1 of a normal (1) and a CF (2) serum pool
were tested against unabsorbed anti-IEF (a) and
the same anti-IEF absorbed 5:1 with a normal
serum pool (b). Both the unabsorbed and the
absorbed antisera were at a concentration of
20%.
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heterozygosity. Only the samples which scored positive for
the CFP doublet showed a positive reaction with antiserum.
Sera from 14 CF homozygotes, 28 CF heterzygotes and
23 normal controls were tested against two batches of
anti-IEF (AS60 and AS82/83), by RIE and IRMA. By selecting
an arbitrary cut-off, between the three different groups,
94% of the samples were correctly assigned as CF
homozygotes, CF heterozygotes or normals.
The RIE peak values depended on the batch of
antiserum used. The results are shown in Fig 4.3.. Each
group of samples has a different median values for the two
different antisera. These are summarised in Table 4.1..
The data was not normally distributed and non-parametric
tests of significance were used in analysis, the Median
test for differences between the medians and the Spearman
rank test for correlation coefficients (Siegel, 1956) The
median values between normal and CF heterozygotes and
between CF heterozygotes and CF homozygotes showed highly
significant differences (p<0.001 in both cases for both
antisera). The correlation coefficient between the values
for the two different antisera was 0.8627, p<0.001.
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In the IRMA the percentage of I Protein A bound to
the different sample groups is shown in Fig 4.4.. The
median values are shown in Table 4.2.. The median values,
between different sample groups, again showed highly
significant differences (p<0.001). The correlation
coefficient between the values for the two different
antisera was 0.8432, pCO.OOl.
Fig.4.3. Relative peak areas of RIE of serum samples
using two different batches of anti-lEF.
CF, CF homozygotes, HZ, obligate CF
heterozygotes, N, normal controls^
The median value of peak areas (mm ) for each
group of sera is indicted by the solid line, the
arbitrary cut-off points for each group is
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TABLE 4.1. Median values of peak areas* for RIE assay.
Sample Number Median AS60 Median AS82/83
CF homozygote 14 >100 >100
CF heterozygote 28 18 15
Normal 23 5 0
2
* Peak area measured in mm
Fig.4.4. Relative percentages of bound radioactivity of
an IRMA of serum samples.
CF, CF homozygotes, HZ, obligate CF
heterozygotes, N, normal controls.
The median value of the bound radioactivity for
each group of sera is indicted by the solid
line, the arbitrary cut-off points for each
group is indicated by the dashed line.
Radioactivity bound is expressed as a percentage



















































TABLE 4.2. Median values of radioactivity bound*, by IRMA.
Sample Number Median AS60 Median AS82/83
CF homozygote 14 56 51
CF heterozygote 29 34 34
Norma 1 23 26 19
* Radioactivity bound expressed as a percentage of the total
radioactivity added.
-52- Chapter 4
These immunoassays showed the potential of using
anti-IEF antisera for detecting CF heterozygotes in the
general population. The blood samples in these series were
all collected in a standard manner, as described for IEF,
and this may be critical in the correct assignment of CF
status.
4.3.3. Immunodep1etion of anti-IEF rockets.
To establish that the antiserum, produced in guinea
pigs, was not against a common known protein, serum
samples were run by RIE through a high concentration of
several commercially available polyclonal antisera before
reacting with anti-IEF.
The antisera which were tested for immunodep1etion of
the anti-IEF peak are shown in Table 4.3..
All of these antibodies failed to immunodep1ete the
anti-IEF precipitin peak and the protein was therefore not
one of these common well characterised serum proteins.
CF homozygote serum was also tested for depletion of
the anti-IEF peak with Protein A-Sepharose CL-4B. This
depletion experiment showed no reduction in the level of
antigen in serum.
4.3.4. Gel filtration of serum.
The profiles of sephacryl S300 gel filtration of a
normal serum pool and a CF serum pool are shown in
Fig.4.5..By plotting the MW of the protein standards
versus their elution volume the MW of the anti-IEF
Table 4.3. Polyclonal antisera used to immunodeplete
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Fig.4.5. Sephacryl $300 gel filtration profiles of normal
and CF serum pools.
The anti-IEF positive fractions on the CF serum
profile are indicated by the hatched area. The
MW of these fractions was estimated by comparing
their elution volume with the elution volume of




*1 Bovine serum albumin ; 67 kd
»2 Ovalbumin ;£5kd
x3 Chymotrypsinogen A ;25kd






positive fractions can be estimated, the anti-IEF
positive fractions elute at a MW range of 51-60
ki1oda1 tons (kd).
4.3.5. Polyacry1 amide gel electrophoresis.
The pooled anti-IEF positive fractions from
sephacryl S300 gel filtration of a CF serum pool and the
equivalent fractions from a normal serum pool were run
on 15% acrylamide-SDS gels. The gels were stained with
Kenacid Blue (Fig.4.6.a) followed by the more sensitive
silver staining (Fig4.6.b).
There were no observed differences in the
electrophoretic patterns of CF and normal fractions with
Kenacid Blue or silver staining. The protein reacting
with anti-IEF may be masked by one of the other serum
proteins or the level may be too low to observe by these
methods.
4.3.6. Affinity purification.
The production of a polyclonal antiserum made it
possible to consider purification of the protein by
affinity chromatography.
The immunologically reactive component of a CF serum
pool was bound to a CNBr-sepharose anti-IEF column.
Attempts to elute the bound fraction by change in pH were
unsuccessful. Use of the polarity reducing reagent
ethylene glycol at pH 8.0 and pH 11.0 resulted in a
fraction which reacted with anti-IEF. The results are
kd a m ■ b
M 12 12
Fig.4.6. SDS-PAGE of gel filtration fractions.
SDS-PAGE of serum fractions separated on a
sephacryl S300 gel filtration column : 1) the
pooled anti-IEF positive fractions (MW 51-60kd)
from a CF serum pool, 2) the pooled MW 51 -60kd
fractions from a normal serum pool, stained with
Kenacid Blue (a) and silver (b). Lane M shows
the MW markers.
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illustrated in Fig 4.7..
The purification of the protein from CF serum by
affinity chromatography was seen to be possible. However,
the purified protein appeared extremely unstable. The
protein isolated by eluting with 50% ethylene glycol, pH
11.0, when retested 24 hr after purification, no longer
showed a positive reaction. The reason for this is
unknown. The amount of material purified by this method
was judged to be less than 20% of the original
concentration in serum by measuring the area under the
precipitin rocket. This indicated that 80% of the protein
was either still bound to the CNBr-Sepharose anti-IEF, or
was lost in the concentration step, or that the majority
of the protein had lost its immunological activity. To
acertain whether the column contained any more protein,
further elution using chaotropic agents was attempted.
The column was washed sequentially with 1M MgC^j 2M
MgC12, 3M MgC12, 1M KSCN, 2M KSCN and 3M KSCN. The
fractions were collected, concentrated to the original
serum volume and tested against anti-IEF by RIE. These
were all negative and no further detectable antigen could
be eluted.
The persistent problems of purification may be due to
the antigen being unstable. If the material could be
purified at higher concentrations then this problem might
be overcome. However, limited quantities of anti-IEF and
CF serum made this method for producing large quantities
of purified material impractical.
Fig. 4.7. RIE of CF serum fractions eluted from an
anti-IEF immunoaffinity column.
A CF serum pool (1) was loaded onto a
CNBr-sepharose anti-IEF immunoaffinity column.
The unbound fraction was eluted with PBS (2)
and the bound fractions were eluted with 50%
(v/v) ethylene glycol either pH 8.0 (3) or pH
11.0 (4). 20p 1 of each of the concentrated
fractions (2-4) and the CF serum pool were run
against 20% anti-IEF.
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4.3.7. Comparison of the properties of the protein
identified by anti-IEF with CFP.
The properties of CFP described by Wilson (1982) and
the properties of the protein defined by anti-IEF are
summarised in Table 4.4. The pi of CFP is 8.46 and it can
only be assumed that the anti-IEF protein has the same pi,
as the antiserum was produced from the portion of gel at
that pH. The discrepancy in molecular weight, the apparent
difference in complexing to IgG and binding to Protein A
indicate that the 2 proteins are different. Therefore the
protein defined by anti-IEF was named CF Antigen (CFAg).
4.3.8. Identification of a tissue source for CFAg.
CFAg was tested for in the most easily available
human materials, saliva, urine, erythrocytes, MNL and
PMNL.
All saliva and urine samples were negative when
tested against anti-IEF.
Blood samples were collected into sodium heparin
tubes from 3 CF homozygotes, 3 CF heterozygotes and 3
healthy controls. The samples were fractionated into three
cell types, erythrocytes, MNL and PMNL. Each cell type was
divided into a cytoplasmic and a membrane fraction. The
erythrocytes and MNL were negative when tested against
anti-IEF. However, the cytoplasmic fraction of PMNL showed
a very strong reaction with anti-IEF in all three
genotypes
Identification of PMNL as a source of CFAg indicated
Table 4.4. Comparison of the properties of CFP and the
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with IgG
MW 51-60 kd in serum.




the possibilty of using leukaemia cells, which are
available in large numbers in a small blood sample.
Cells were separated from blood collected from 14
CML patients. The cytoplasmic fraction of 12 of these
samples was strongly positive against anti-IEF. The 2
samples from patients in blast crisis were negative.
4.3.9. Guinea pig antiserum to CML granulocyte lysate
(anti-CML ).
8 guinea pigs were used to produce antiserum to CML
lysate. The antiserum in its unabsorbed state produced a
monospecific antiserum, by RIE, against a component in CF
homozygote serum which was absent in normal serum.
(F i g. 4.8.)
The quantity of antiserum required for visualisation
of rockets was much lower than with anti-IEF and was
optimised at 3% with a 20pl serum sample.
4.3.10 Comparison of anti-IEF and anti-CML.
The identity of the 2 polyclonal antisera was
established by using Ouchterlony doub 1 e-diffusion. The
antigen and antibody were placed in wells punched in
agarose gels and allowed to diffuse. A straight line of
precipitate is formed where concentrations of diffusing
antibody and antigen reach equivalence. The ideal
concentrations of antibody and antigen will produce a
precipitin line midway between the two wells. In an
unbalanced situation, in which there is a great excess of
Fig 4.8. RIE of a normal and a CF serum pool against
unabsorbed anti-CML.
2Op 1 of a normal (1) and a CF (2) serum pool
were tested against unabsorbed anti-CML at an
antiserum concentration of 20%.
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antigen or antibody, multiple precipitates may form due to
alternate so 1 ubi1isation and reprec i pitation. To establish
optimum concentrations, antigen or antibody is placed in a
central well with serial dilutions of the other round it.
In a reaction of complete identity there is a continuous
precipitate formed.
Results are shown in Fig 4.9.. The continuous
precipitate formed shows complete identity between
anti-IEF and anti-CML using CF homozygote serum or CML
lysate as an antigen source. This technique also shows a
line of complete identity between the 2 antigen sources.
4.3.11. Chromosomal assignment of CFAg.
Four subclone series of somatic cell hybrids (WEMAD
1., WEMAD 2, WEH and WEP) were produced, each derived from
an independent fusion.
Cell lysates were produced from 15 subclones derived
from the 4 hybrid lines and tested against anti-CML by
Ouchterlony double diffusion. The results are summarised
in Fig 4.10.. Lysates of the leukaemic cells and WEHI-TG
from which the hybrids were derived were also tested by
the same method.
All four leukaemic cells were positive for CFAg,
whilst the mouse myeloid stem-cell line was negative.
Analysis of the Ouchterlony results and the karyotypes
showed that CFAg segregated with human chromosome 1 with
complete concordance.
Fig 4.9. Ouchterlony double diffusion of anti-IEF and
anti-CML against CF serum and CML granulocyte
lysate.
1, 2Op 1 of anti-IEF. 2, 20p1 of anti-CML.
3, 2 0 p1 of CF serum pool. 4, 2 Op 7 of a g 1 /10
dilution of CML granulocyte lysate (10 cells/ml
of PBS).
A line of complete identity is formed between
anti-IEF and anti-CML against both CF serum and
CML granulocyte lysate. There is also a line of
complete identity between CF serum and CML
granulocyte lysate against both antisera.
Fig.4.10. Segregation of human chromosomes and CFAg in
hybrid cell lines.
The filled squares show the presence of a human
chromosome in more than 30% of cells karyotyped.
Open squares show the absence of the chromosome
in more than 95% of cells karyotyped.
The shaded squares show the presence of CFAg





A polyclonal antiserum has been produced against the
portion of IEF gel pH 8.4 to 8.5 as described by Manson
and Brock (1980). A large series of serum samples,
collected in a standardised way, were tested against two
batches of anti-IEF by RIE. The results confirmed the
earlier observation that there was an elevated level of a
specific protein in CF homozygotes, an intermediate level
in obligate heterozygotes and a low level in healthy
controls. The same samples were also assayed by an IRMA
based on the same two batches of anti-IEF. Both these
assay systems detected 94% of the genotypes correctly and
showed the potential of using these assays to identify CF
heterozygosity in a general population.
The availability of anti-IEF enabled some biochemical
characterisation of the protein which it identified.
Immunodepletion of CF serum using several commercially
available polyclonal antisera or depletion with Protein-A
sepharose failed to remove or reduce the immunological
activity of the protein. Gel filtration of a CF homozygote
pool of serum indicated a fraction of MW of 51 -60kd which
reacted with anti-IEF. SDS-PAGE of the positive fraction
showed no difference in the banding pattern when compared
with the equivalent fraction from a normal serum pool.
The protein defined by anti-IEF showed several
different properties to CFP as described by Wilson (1982).
Immunodepletion experiments show that, unlike CFP, it does
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not bind to protein-A or IgG. The apparent MW in serum is
51-60kd compared with 90-180kd for CFP. Therefore, this
protein was named Cystic fibrosis antigen (CFAg).
Immunopurification of CFAg, from CF serum, was
attempted using solid phase anti-IEF. It was possible to
elute immunologically active CFAg with 50% ethylene
glycol, pH 11.0. However, this material appeared extremely
unstable and if retested after a short period of storage
at 4°C was no longer detectable immunologically.
The tissue source of CFAg in serum was identified as
granu1ocytes. Antiserum to CFAg was more easily produced
in guinea pigs using a CML granulocyte lysate as the
immunogen. This antiserum (anti-CML) appeared monospecific
against a component in CF serum when tested by RIE.
Anti-IEF and anti-CML reacted with the same protein
in serum and CML granulocyte lysate as shown by lines of
complete identity when tested by Ouchterlony double
diffusion. This method also showed that the antigen in CF
serum was identical to the antigen in CML granulocyte
lysate.
Localisation of CFAg in CML granulocytes made it
possible to produce somatic cell hybrids using a mouse
stem cell line and CML granulocytes. The cell lines were
checked for expression of CFAg by Ouchterlony double
diffusion. All cell lines produced were karyotyped and
expression of CFAg was restricted to those cell lines
which retained human chromosome 1. The localisation of
CFAg on chromosome 1 excludes the possibility of it being
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the basic defect in CF, as linkage studies have shown that
the mutant gene for CF is on chromosome 7 (Beaudet et a 1.,
1986). Nevertheless, the observed elevation of CFAg in the
serum of CF homozygotes and heterozygotes may be due to
the involvment of CFAg in some biochemical or physiological
pathway which is altered in CF.
There were many problems encountered both in the
production of antiserum and in using this antiserum to
characterise and purify CFAg. It was possible that if
monoclonal antibodies could be produced against CFAg, they
would not only improve the assay system, but also be






In 1975 Kohler and Milstein described a technique to
produce large quantities of antibodies by fusing myeloma
cells with B-lymphocytes.
By immunising an experimental animal (usually a
mouse) with an antigen of interest it is possible to
stimulate lymphocytes to produce antibodies which
recognise this antigen. The mouse is then killed and the
lymphocytes collected from the spleen. These are then
fused with a myeloma cell line to produce hybrids which
grow as rapidly as myeloma cells but still retain their
antibody production derived from the p-lymphocytes. This
method of priming mouse lymphocytes to produce specific
antibodies still leaves many fused lymphocytes producing
irrelevant antibodies. Even the best immunisation
schedules with highly immunogenic, partially purified,
antigen may only produce a few percent of fusions
secreting the specific antibody desired.
In all fusions, before further cloning, these antibody
secreting hybrids must be selected by screening.
Essentially this primary screening must be simple, cheap
and fast to deal with large numbers of hybrids and
identify those of interest. This is particularly important
in highly successful fusions where several hundred hybrids
may result, since it is impractical to maintain them all in
culture for any length of time.
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The choice of immunogen and screening method is
dependent on the antibody required. With carefully
designed screening it is possible to isolate a specific
antibody from a wide variety of antibodies produced by
immunisation with crude material.
5.1.2. Monoclonal antibodies to CFAg.
The production of polyclonal antibodies to CFAg
indicated the potential of using this protein to detect CF
heterozygosity in the general population. In the
expectation of improving this detection test it was
decided to raise monoclonal antibodies to this protein
even though it had not been purified or well
characterised.
5.1.3. Strategy.
Monoclonal antibodies can be made against any
substance that can be recognised as an antigen by cells in
an animal immune system. When a crude mixture of
substances is injected into an animal a series of
antibodies are made which recognise different components
of the antigen mixture. In the process of fusion the whole
spleen is used as the source of lymphocytes. Many fused
lymphocytes will be against antigens of no interest.
Therefore, each hybridoma supernatant must be screened to
select the specific monoclonal antibodies required.
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a) Immunogens.
The first step in producing a monoclonal antibody to
a defined antigen is to select a suitable preparation of
the antigen for immunisation.
When it was first decided to produce monoclonal
antibodies against CFAg the only known source of CFAg was
CF homozygote or heterozygote serum. Some form of
partially purified CFAg, derived from CF serum, could be
used to immunise mice and the specific monoclonal
antibodies selected by analysis after cloning.
The portion of IEF gel pH 8.4 to 8.5 from IEF of a CF
serum pool had successfully produced a polyclonal
antiserum in guinea pigs and there was no reason to
believe that this same immunogen would not produce
antibodies in mice.
The technique of immunisation with immunoprecipitins
has been used with great success to produce high titre
polyclonal antisera against several serum proteins
(Kro11, 1981). The immune-complex formed from RIE of CF
serum against anti-IEF is a partially purified source of
CFAg. Well washed immunoprecipitins will contain guinea
pig Ig as a major contaminant but few other proteins and
should contain sufficient CFAg to produce antibodies.
CML granulocyte lysate is an abundant source of CFAg.
It was considered that the lysate contained sufficient
CFAg, in relation to other proteins, to be suitable for
use in immunising mice without further purification.
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b) Immunisation.
Initial immunisation of antigen is given
sucutaneously. The IEF homogenate and RIE precipitins are
insoluble forms of antigen and will ellicit a strong
antibody response. The CML granulocyte lysate is a soluble
form of antigen and can be mixed with an immune system
stimulant, such as Freund's adjuvant, which primes the
immune system to recognise avidly any antigen injected
with it.
The final boost of antigen is given intravenously and
intraperitonea1ly 3-4 days prior to removal of the spleen
to ensure that B cell clones are maximally stimulated. The
intravenous immunisation ensures that a large number of
B-cells will be stimulated simultaneously. These rapidly
dividing cells grow best after fusion.
c) Primary screening.
Design of the primary screening system is crucial
if specific monoclonal antibodies are to be identified. A
poor screening method will fail to identify the hybridomas
required. When dealing with hybridomas from an impure
immunisation it is preferable to screen against an antigen
source which does not have too many other proteins present
in order to limit the number of irrelevant hybridomas
showing a positive reaction. The simplest assays depend on
the ability of a monoclonal antibody to bind to its
antigen. A source of antigen can be immobilised onto PVC
microtitre plates by incubating at an alkaline pH. The
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hybridoma supernatants are incubated with the antigen and
the excess washed off. The binding reaction can be
detected by using an enzyme-labelled second antibody
against the monoclonal antibody.
Hybridoma supernatants can be screened for
immunological activity against any partially purified
source of CFAg.
The CFAg positive fraction from Sephacryl S300 gel
filtration contains several serum proteins (see Fig.4.6.)
and it was thought that a negative control using
the equivalent fraction from gel filtration of a normal
serum pool would considerably reduce the number of
positive hybridomas selected.
CFAg was immunopurified on a CNBr-sepharose-anti-IEF
column and eluted with 50% ethylene glycol pH 11.0 (see
Fig.4.7.). The immunopurified protein seemed very
unstable and it could no longer be detected by RIE with
anti-IEF after a short storage time. However it was
possible that sufficient CFAg remained to be detectable in
a more sensitive enzyme immunoassay system.
CML granulocyte lysate contained sufficient CFAg to be
used directly without further purification.
d) Secondary screening.
CFAg is a protein defined by it's immunological
reactivity with a polyclonal antiserum (anti-IEF).
The secondary screening method must relate directly to
this original definition. Immunodepletion of the CFAg
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rocket from CF serum, using hybridoma supernatants,
directly relates the immunospecificity of the monoclonal
antibodies to the polyclonal antiserum.
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5.2. Methods.
5.2.1. Immunisation of mice and production of hybrids.
The production of hybridomas began before the
identification of granulocytes as a major source of CFAg
and early immunisations used either the homogenised
portion of IEF gel (as described for the production of
anti-IEF; section 4.2.1.) or the homogenised precipitin
peaks derived from RIE of CF serum. Later CML granulocyte
lysate, (as described for the production of anti-CML;
section 4.2.18.), was used. In all cases BALB/c mice were
initially immunised subcutaneously with antigen
preparation. After four weeks they were boosted with the
same material intravenously and intraperitonea1ly. Four
days later the spleen was removed and the cells hybridised
with P3 NSl/Agl-4 myeloma cells. The fused cells were
plated and sub-cloned as described in van Heyningen et al.
(1982). The immunisation protocols are summarised in Table
5.1.
5.2.2. Primary screening of hybridoma supernatants.
Primary screening of the culture supernatants was by
enzyme-1inked immunoabsorbent assay (ELISA). Supernatants
from clones produced by immunisation with the IEF pH
8.4-8.5 homogenate were tested against the Sephacryl S300
gel filtration CFAg positive fraction and the equivalent
fraction from normal serum; section 4.2.4.. Those with a
stronger reaction against the CFAg positive fraction were
Table 5.1. Immunisation protocols for the production of
monoclonal antibodies to CFAg.
Fusions 1-3
Immunogen The portion of IEF gel pH 8.4-8.5 from IEF
of a CF serum pool, lg of gel homogenised
in 1ml of PBS.
Primary
Immunisation
0.2ml of homogenate per mouse.
Secondary
Immunisat ion







The precipitin peaks from CF serum pool
RIE against anti-IEF. Rockets from 200 pi of
serum homogenised in 1ml of PBS.
0.25ml of homogenate, emulsified with an
equal volume of Freund's complete adjuvant
(FCA), per mouse.
0.25ml of homogenate, emulsified with an
equal volume of Freund's incomplete








CML granulocyte lysate 10 cells per ml of
PBS (3mg/ml protein).
0.15mg of protein, emulsified with an
equal volume of FCA, per mouse.
0.15mg of protein, emulsified with an
equal volume of FIA, per mouse.
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selected for further testing. The supernatants were also
tested against ethylene glycol pH 11.0 immunopurified
material; section 4.2.10.
50p1 of diluted Sephacryl S300 fraction (lpg
protein/ml) or ethylene glycol pH 11.0 immunopurified
material (lpg protein/ml), in 0.1M glycine buffer pH 9.5,
was incubated overnight at 4°C in PVC microtitre plates.
The plates were washed in 0.9% sodium chloride containing
0.05% Tween 20 (sa1ine/Tween). 50pl of hybridoma culture
supernatant was added, incubated for 1 hr at RT and the
excess washed off with sa1ine/Tween . 5Op 1 of
peroxidase-conjugated sheep anti-mouse Ig (Serotec),
diluted 1/1000 in PBS containing 0.1% BSA and 0.05% Tween
20 (diluent), was added and incubated for 1 hr at RT.
After washing, the peroxidase was developed for 30 min by
adding lOOpl of a solution containing 20mg of
o-phenylenediamine and 20p1 of lOOvol hydrogen peroxide in
100ml of 0.1M citrate buffer pH 5.0. The reaction was
stopped by adding 50p1 of 4M sulphuric acid and the plates
read at 492nm on a Titretek Multiscan.
The culture supernatants from the clones resulting
from the immunisations with RIE precipitins and CML
granulocyte lysate were screened against CML granulocyte
lysate dilute 1/1000 in 0.1M glycine buffer pH 9.5 and
coated onto PVC plates. CML granulocyte lysate appeared to
contain much higher levels of CFAg than any of the serum
derived materials. The remainder of the procedure was as
described above.
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5.2.3. Secondary screening of hybridoma supernatants.
All culture supernatants positive in the primary
screening were tested for specificity towards CFAg.
Immunodepletion of the antigen in CF serum was
detected by RIE. 200pl of culture supernatant was
incubated with lOOpl of a 10% (v/v) concentration of solid
phase donkey anti-mouse Ig (SAC-CEL, Wellcome) with mixing
for 1 hr at RT. The SAC-CEL was pelleted by centrifugation
and washed three times in sa1ine/Tween. 20pl of CF serum
pool was added to the pellet and incubated, with mixing,
for 1 hr at RT. The mixture was centrifuged and the
depleted serum run against anti-IEF by RIE.
5.2.4. Further screening of non-depleting antibodies.
Hybridomas, produced by immunisation with IEF pH
8.4-8.5 homogenate, which showed no immunodepletion of
CFAg, but were positive in primary screening, were further
tested to check whether the fusion had been successful and
had produced secreting clones against other proteins.
The assay system devised used commercially available
polyclonal antisera to bind proteins from CF serum. The
hybridoma supernatant was then incubated with the antigen
bound to polyclonal antisera. The presence mouse Ig
detected by labelled second antibody indicating the
specificity of the monoclonal antibody.
50pl of commercially available polyclonal antisera,
ant i- albumin, anti-IgG, anti-IgM, anti-a2M>
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anti-transferrin and anti-C3a, diluted 1/1000 in 0.1M
glycine pH 9.5 was incubated, on PVC plates, overnight at
4°C. After washing, 50pl of CF serum pool, 1/100 and
1/1000 in diluent, was incubated for 2 hr at RT. 50pl of
hybridoma culture supernatant was added to the washed
plates and incubated for 2 hr at RT. The mouse Ig binding
was detected as described above.
5.2.5. Subtyping of monoclonal supernatants.
50p 1 of sheep anti-mouse Ig (Dako) (Ipg/ml in 0.1M
glycine buffer pH 9.5) was incubated in microtitre plates
at 4°C overnight. The plates were washed in saline/Tween
and then blocked with 1 % BSA in PBS for 1 hr at RT.
Hybridoma supernatants diluted 1/500, 1/1000 and 1/2000 in
0.1% BSA/PBS were incubated for 2 hr at RT. After washing,
peroxidase conjugated anti-IgGl diluted 1/1000, anti-IgG2a
diluted 1/1000, anti-IgG2b diluted 1/2000 and anti-IgM
diluted 1/1000 (all from Serotec) ,in 0.1% BSA/PBS were
incubated for 2 hr at RT. The peroxidase was developed as
described above.
5.2.6. Radiolabel1ing of granulocyte lysate.
A CML granulocyte lysate was labelled by the
chloramine-T method (Bolton, 1977).
CML granulocyte lysate containing 20pg of protein was
mixed with lOpl of 0.25M potassium phosphate pH 7.5, lmCi
of sodium iodide and lOpl of chloramine-T (1.6mg/ml in
0.25M potassium phosphate pH 7.5). After mixing for 15
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sec, 1 Op 1 of cysteine (0.56mg/ml in phosphate buffer) and
lOOpl of potassium iodide (10 mg/ml in phosphate buffer)
was added.
A sepharose G50 column was equilibrated with PBS
containing 0.1% BSA and 0.02% sodium azide. The iodinated
material was loaded onto the column and fractions
containing the labelled protein were collected. The
labelled material was diluted in PBS containing 0.1% BSA
to give 5xl07cpm/ml.
5.2.7. Dilution curves of immunodepleting monoclonal
supernatants.
The labelled granulocyte lysate (1ml) was
pre-absorbed with 4ml of 10% SAC-CEL donkey anti-mouse Ig,
to remove any labelled material which binds
non-specifically to the SAC-CEL. Serial 10-fold dilutions
in diluent were incubated with pre-absorbed labelled
lysate (1.7 x lO^cpm) overnight at RT. lOOpl of SAC-CEL
donkey anti-mouse Ig was added and incubated for 2 hr at
RT. The mixture was washed with 3ml of saline/Tween and
the pellet counted.
5.2.8. Epitope analysis by competition binding.
All proteins are made up of several different
antigenic fragments known as epitopes. Each monoclonal
antibody detects one antigenic determinant of a protein.
Therefore, monoclonal antibodies used to devise a two-site
sandwich ELISA must detect different epitopes. Epitope
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analysis is designed to define the antigenic determinant
identified by each monoclonal antibody by comparing it's
binding to a labelled antigen in competition with other
antibodies.
PVC plates were coated with rabbit anti-mouse Ig
(Dako) diluted 1/1000 in 0.1M glycine buffer, pH 9 5.
After 2 hr incubation at RT the plates were washed and
50pl of monoclonal supernatant added and incubated for 1
hr at RT. After further washing 5Op 1 of non-immune mouse
serum diluted 1/200 in diluent was added, to block
unoccupied antibody sites, and incubated for 1 hr at RT. A
second monoclonal supernatant (50p1), pre-mixed for 30 min
with SAC-CEL pre-absorbed labelled granulocyte lysate
(35000cpm), was added and incubated overnight. After
further washing individual wells of the plates were cut
out and the bound label counted.
5.2.9. Immunoprecipitation of labelled antigen recognised
by monoclonal supernatants and guinea pig
anti-CML.
Radio 1 abe11ed granulocyte lysate was pre-absorbed
with an equal volume of Protein-A sepharose (Pharmacia),
10% w/v in PBS, to remove any non-specific binding of the
labelled proteins to the protein-A sepharose, before use
in immunoprecipitation.
lOOpl of a 10% (w/v)mixture of Protein-A sepharose
was washed three times in saline/Tween before incubation
with 200pl of a mixture containing equal volumes of all
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positive monoclonal supernatants, for 2 hr at RT. A
mixture of anti-a-fetoprotein monoclonal supernatants was
used as a negative control. The sepharose was washed a
further three times before the addition of 5Op 1 of
Protein-A pre-absorbed 125I labelled CML lysate (5xl05cpm)
and incubation overnight at 4°C. The pellet was washed
three times with 0.1M Tris buffer pH 6.8 containing 0.5M
lithium chloride and 1% (v/v) mercaptoethano1. The
immunoprecipitated label was eluted by boiling in sample
buffer and run on 15% polyacrylamide SDS gels as described
earlier (section 4.2.5.).
Immunoprecipitation using guinea pig anti-CML was as
above, except that 20p1 of the polyclonal antiserum
replaced the monoclonal supernatant. Non-immune guinea pig
serum was used as a negative control.
The e 1 ectrophoresed gel was fixed in 50% ethanol, 10%
acetic acid (v/v) in distilled water for 30 min. The gel
was then vacuum dried onto 3MM filter paper and exposed
onto pre-flashed x-ray film.
5.2.10. Production of ascites.
Ascitic fluid was produced by growing subclones of
hybridomas as ascitic tumours in BALB/c mice pretreated
with pristane.
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5.2.11. Purification of ascitic fluid antibodies.
Protein content of ascitic fluid was determined by
the method of Lowry et a 1. (1951).
All purification steps were at 4°C. Ascitic fluid
diluted to 10 mg/ml protein in PBS was added to an equal
volume of saturated ammonium sulphate and mixed overnight.
The mixture was centrifuged and the precipitate washed
twice with cold saturated ammonium sulphate. The
precipitate was resuspended in PBS and dialysed, with
three changes, against PBS, overnight. 'The protein
concentration of the dialysed material was measured.
The PBS in 2.5ml of dialysed ascites was exchanged in
a PD10 column (Sephadex G25 Pharmacia) with 0.05M
2-(N-morpho1ino) ethane-sulfonic acid (MES) containing
0.005M sodium chloride pH 6.0 (start buffer).
The Ig was further purified by use of a cation
exchange column adapted for use with fast protein liquid
chromatography equipment (FPLC, Pharmacia).
A Mono S HR 5/5 column was equilibrated with start
buffer. The ascites, in start buffer (4ml) was loaded onto
the column at a flow rate of 0.5ml/min. After 8 min the
bound Ig was eluted in a gradient formed by adding 0.05M
MES with 1M sodium chloride up to a concentration of 25%
(v/v) in start buffer. Protein remaining bound to the
column was eluted with 100% 0.05M MES with 1M sodium
chloride.
The fractions containing the specific Ig were
identified by screening against CML granulocyte lysate,
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diluted 1/1000 in 0.1M glycine buffer pH 9.5, coated onto
plates, as previously described.
5.2.12. Biotinylation of ascites Ig.
The purified Ig was dialysed against 0.2M borate
buffer pH 8.0 and diluted to a protein concentration of
lmg/ml in the same buffer. lOOpl of
N-hydroxysuccinimidobiotin (lmg/ml in dimethylsulphoxide)
was added to 1ml of Ig. After 4 hr at RT the mixture was
dialysed against PBS with 0.02% (w/v) sodium azide and
stored in small aliquots at -70°C until use.
5.2.13 Development of a sandwich assay.
Development of a two-site sandwich assay requires two
antibodies which recognise different epitopes of an
antigen. The first antibody must retain its immunological
function either when bound directly to a solid-phase (PVC
plates) or indirectly to an anti-mouse Ig previously bound
to a solid phase. A suitably diluted antigen source
incubated with the first antibody can be detected by a
labelled second antibody. The amount of second antibody
bound is proportional to the amount of antigen present.
Levels of antigen can be determined by comparing with a
standard curve.
The purified ascites were all tested in a sandwich
assay. The best antibody pair was selected by
biotinylating each antibody and testing against each
possible coating antibody in an ELISA using CML
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granulocyte lysate as an antigen source. By comparing the
dilution curves of CML granulocyte lysate in each of these
pairs, the pair giving the greatest range of detection of
antigen was chosen as the basis of the assay. These were
CF356 as coating antibody and biotinylated CF344 as second
antibody.
PVC plates were coated with 50p1 of ascites CF356
diluted 1/1000 in 0.1M glycine pH 9.5 and incubated for 2
hr at RT. Plates were washed and then blocked with 0.5%
(w/v) BSA in PBS. 50p1 of a preparation of CML granulocyte
lysate in doubling dilutions from 1/5000 to 1/640000 was
used as an antigen standard. Serum pools, from CF
homozygotes, heterozygotes and normal controls were tested
to determine the range and sensitivity of the assay
system. Serum samples diluted 1/100, 1/500, 1/1000 and
1/2000 or diluted standards were incubated overnight at
4°C. After washing, 50p 1 of biotinylated CF344, 1/1000 in
diluent, was added and incubated for 1 hr at RT. After
further washing streptavidin-peroxidase (Amersham), 1/1000
in diluent, was added for 30 min at 35°C. Peroxidase was




The results of the fusions attempted to produce
monoclonal antibodies to CFAg are summarised in Table
5.2. .
In the primary screening of hybridomas, produced in
fusions from immunisation with IEF homogenate, against
sephacryl S300 fractions all supernatants which showed a
higher level in the CFAg positive fractions than in the
normal were considered positive. Also all supernatants
which reacted with the ethylene glycol pH 11.0
immunopurified material were treated as positive.The three
IEF homogenate fusions failed to produce any specific
antibodies to CFAg as defined by the immunodepletion of
antigen from CF serum in RIE.
However, further testing against common serum
antigens identified forty-two antibodies to albumin,
twenty-two to IgG, one to transferrin and one to The
remaining twenty-six supernatants were positive when
tested against the sephacryl S300 fraction, from CF serum,
but their specificity was not identified. Twenty-two
supernatants were positive against the immunopurified
material: these were all antibodies to IgG.
Immunisation with RIE immunoprecipitins produced four
specific antibodies and immunisation with CML granulocyte
lysate produced six. Immunodepletion of CFAg in CF serum
by these ten monoclonal antibodies is shown in Fig.5.1..
Table 5.2. Outcomes of fusions attempted to produce
monoclonal antibodies to CFAg.
Immunogen Number Number Number Number
of of wells Positive, Positive,
fusions tested Primary Secondary
Screening Screening
IEF homogenate 3 1437 92 0
RIE precipitins 2 1018 84 4
CML lysate 1 352 75 6
Fig.5.1. Immunodepletion of CFAg from serum using
monoclonal supernatant!.
Immunodepletion of the rocket formed by RIE of CF serum
against anti-IEF. A reduced or depleted rocket indicates
a monoclonal antibody against the same protein as
anti-IEF.
Non-specific antibodies in wells 2,3,5,10, and 11.
Specific antibodies in wells 1 (CF31), 4 (CF145), 6
(CF297 ), 7 (CF320), 8 (CF344), 9 (CF345 ), 12 (CF557), 13
(CF46), 14 (CF285 ) and 15 (CF356 ). The negative control
with an irrelevant monoclonal (anti-aFP) in well 16. CF
serum sample in well 17.
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5.3.2. Subtypes of monoclonal supernatants.
Subtyping of the 10 monoclonal antibody supernatants
identified seven to be IgG1, two to be IgG2b and one to be
IgM.
5.3.3. Dilution curves.
All the immunodepleting supernatants were tested
against labelled CML granulocyte lysate by dilution
analysis. The resulting dilution curves gave a crude
estimate of the affinity ranking for each antibody (van
Heyningen et a 1 . 1983). The curves are shown in Fig.5.2..
All the monoclonals, except for CF297, exhibited a maximum
binding of approximately 3-4% of the total label added.
CF297 had a maximum binding of only 0.5% indicating that
it was very weak and therefore unsuitable for further
studies.
5.3.4. Epitope analysis.
The very similar binding curves of the nine
monoclonal antibodies allowed epitope analysis to be
performed. The percentage binding of labelled CML
granulocyte lysate to an immobilised first antibody in the
presence of a competing second antibody is shown in Table
5.3.. The observed antigen level in the absence of a
second antibody is taken as 100%. There were at least two
epitope groups.
Fig.5.2. Dilution curves of monoclona1 antibodies against
labelled CML granulocyte lysateT
a) Dilution curves of monoclonals produced from
immunisation with rocket immunoprecipitins from CF serum
against anti-IEF.
b) Dilution curves of monoclonal produced from
immunisation with CML granulocyte lysate.
8000 i x CF 557
Table 5.3. Epitope analysis: percentage binding of
labelled granu 1 ocyte lysate, preincubated with a competing
second antibody, to immobilised first antibody.




31 145 320 344 345 557 46 285 356
31 4 82 35 53 0 0 16 0 0
145 77 0 62 0 85 73 86 76 86
320 78 87 6 129 105 116 144 103 103
344 50 29 21 8 39 49 111 71 60
345 9 76 95 51 0 7 29 0 9
557 17 73 100 56 0 0 15 0 2
46 81 101 91 53 32 0 46 63 63
285 37 105 58 46 0 4 39 0 19
356 66 126 125 103 23 31 47 26 30
-79- Chapter 5
1 : CF31, CF46, CF285, CF345, CF356, CF557.
2 : CF145, CF344.
Uncertain : CF320
5.3.5. Immunoprecipi tat ion.
Immunoprecipitation of the labelled antigen reacting
with monoclonal antibodies and with guinea pig antiserum
is shown in Fig.5.3..
Two specific bands, MW 14 k d and 11. 5 k d , are
precipitated with monoclonal supernatants. These same
bands are precipitated with anti-CML along with extra
bands at 21kd and 9.5kd.
5.3.6. Purification of monoclonal antibodies.
Use of ammonium sulphate precipitation in conjunction
with cation exchange chromatography rapidly produces
material suitable for use in immunoassay. These purified
antibodies were either used directly as coating antibody
or biotinylated before use as second antibody. An example
of a chromatography profile (CF344) and the identified
antibody fractions is shown in Fig.5.4..
5.3.7. Sandwich assay.
The pair of antibodies giving the widest range of
detection of antigen in CML granulocyte lysate was chosen
as the basis for development of a two-site sandwich assay.






1 2 3 4 5
Fig.5.3. Immunoprecipitation of proteins from
radiolabeled CML granulocyte lysate reacting
with monoclonal and polyclonal antibodies
against CFAg.
1, CML granulocyte lysate; 2, Mixed monoclonal
supernatants against CFAg (CF145, CF344, CF557 and CF356
v/v); 3, Monoclonal supernatant against aFP (AFP 161);
4, Guinea pig anti-CML; 5, Non-immune guinea pig serum.
The MW's of immunoprecipitated proteins are indicated.
Fig.5.4. Purification of monoclonal ascites Ig, from
CF344, by cation-exchange chromatography.
The solid line shows the protein absorbance profile at
A280. The dashed line shows the immunoreactivity against
CML granulocyte lysate detected by peroxidase-conjugated
anti-mouse Ig at A492. The shaded area indicates the
fractions pooled as purified Ig.
Elution volume (ml)
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CF344 as second antibody. CML granulocyte lysate was used
O
as a standard in all assays. The antigen present in 10
cells/ml was given an arbitrary value of 107units (U)/ml.
The standard curve covers a range of 62.5-1OOOU as
shown in Fig.5.5.. Serial dilutions of serum pools gave
readings parallel to the standard curve. Antigen
concentration in the CF homozygote pool was greater than
in the heterozygote serum pool which was greater than the
normal pool. The dilution curves are shown in Fig.5.6..
Fig.5.5. Standard curve of CML granulocyte lysate for the








16 31 62 125 250 500 1000 2000
CF ANTIGEN (arbitrary units/ml)
Fig. 5.6. Dilution curves of serum samples in a two-site
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By immunising mice with the IEF homogenate, pH
8.4-8.5 from a CF serum pool, it was possible to produce
hybridomas. However, screening of these hybridoma
supernatants revealed no antibodies with apparent
immunoreactivity against CFAg, as determined by
immunodepletion of anti-IEF rockets. Instead there were
monoclonal antibodies against albumin, IgG,
transferrin and The CFAg positive fractions from
sephacryl S300 contain several serum proteins of which
CFAg is probably a relatively minor component. The CFAg
present must have been largely competed out by other
irrelevant proteins when the fractions were bound to
plates. Therefore, any monoclonal antibodies against CFAg
would have had only a few molecules of protein to bind to
and would have been regarded as negative in the primary
screening system. The material derived from
immunopurification of CF serum on a CNBr-sepharose
anti-IEF column which was used in screening of hybridoma
supernatants had very little CFAg present as determined by
RIE. The amount of CFAg bound to plates may have been too
low to be detected in the screening assay. All the
antibodies which reacted with this material turned out to
be anti-IgG, which was probably due to cross-reaction with
small, but detectable, amounts of guinea pig IgG leaching
from the solid-phase.
Identification of granulocytes as the tissue source
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of CFAg provided a more abundant source of the protein
which led to a successful primary screening procedure
being devised. Screening of supernatants against CML
granulocyte lysate identified monoclonal antibodies
against CFAg. Immunisation with RIE precipitins produced
four stable hybridomas and immunisation with CML
granulocyte lysate produced six stable hybridomas. The
specifity of these monoclonals was established by their
ability to immunodeplete CF serum of CFAg, as detected by
RIE.
SDS-polyacrylamide gel analysis of immunoprecipitated
labelled antigen showed that these monoclonals bound
specifically to proteins of MW 14kd and 11.5kd. Anti-CML
bound to proteins of the same MW, plus extra bands at MW
21kd and 9.5kd. The extra bands detected by the anti-CML
are probably due to it being a polyclonal antiserum
produced against a crude preparation of CML granulocyte
lysate, and therefore reacting with more than one protein
present in the labelled material.
Identification of at least two epitope groups allowed
for the setting up of a two-site sandwich ELISA which
could be used for the quantitation of CFAg in serum
samples. Preliminary testing of the assay using CF
homozygote, CF heterozygote and normal serum pools showed
an elevated level of CFAg in the CF homozygote, an
intermediate level in the CF heterozygote and a low level
in the normal, indicating that the antibody is useful over
a wide range of CFAg levels.
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The production of monoclonal antibodies combined with
the identification of granulocytes as a rich source of
CFAg paved the way for the purification of the protein and





6.1.1. Assay of CFAg in serum samples.
A two-site ELISA assay system was developed for CFAg.
A preliminary series of serum samples (Series 1) was
assayed for CFAg using anti-CML RIE in parallel with the
two-site sandwich ELISA. These assays were firstly to
ascertain whether previous observations of an apparent
link in levels of CFAg to expression of the CF gene
(Manson and Brock, 1980; Bullock et a 1., 1982) were still
demonstrable using anti-CML in place of anti-IEF and
secondly, to check that the levels of CFAg measured by RIE
and ELISA were comparable (Hayward et a 1. 1986).
A second larger series of different serum samples
(Series 2), which included disease controls, was assayed
for CFAg, lactoferrin (Lf) and C-reactive protein (CRP) by
ELISA (Hayward et a 1. ) ♦ ,
CFAg is a granulocyte derived serum protein.
Therefore, any raised level of CFAg observed in sera from
CF homozygotes and CF heterozygotes compared with normal
individuals may be directly attributed either to raised
granulocyte numbers or granulocyte damage due to recurrent
infection. In an attempt to ascertain whether this was
indeed correct the serum level of Lf, a granulocyte
protein found in the specific granules, was measured and
used to 'correct' CFAg values. The level of CRP, an acute
phase reactant, was used as an indication of acute
inflammation caused by infection (Pepys and Baltz, 1983).
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These proteins were also measured in a series of disease
controls. The white cell and granulocyte counts of CF
homozygotes, CF heterozygotes and disease controls were




Serum samples were collected into glass tubes
(Seward) and immediately cooled to 4°C and allowed to clot
for 16-24 hr before centrifugation at 4°C. The samples
were aliquotted into plastic tubes and stored at -70°C
until use.
Series 1: 37 CF homozygotes, 17 obligate CF heterozygotes
and 14 normal healthy controls.
Series 2: 50 CF homozygotes, 34 obligate CF heterozygotes
60 normal healthy controls and 25 disease controls
The disorders of the disease controls are described
in Table 6.1..
6.2.2. Assay of CFAg.
In series 1 CFAg was assayed by RIE using 3% anti-CML
with a 20p1 serum sample and by ELISA as described in
section 5.2.13.. In series 2 CFAg was measured by ELISA.
6.2.3. Assay of Lf.
Monoclonal antibodies to Lf were produced as
described by Chung et a 1 .( 1985). A two-site sandwich assay
was carried out by coating PVC plates with ascitic fluid
from monoclonal antibody B92, diluted 1/1000 in 0.1M
glycine, pH 9.5, and incubating for 2 hr at RT. Plates
were washed and blocked, before addition of serum samples
undiluted, and diluted 1/10, 1/50 and 1/100 in diluent. Lf
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standard was purchased from Sigma. After overnight
incubation at 4°C, biotinylated second monoclonal
antibody, B97, diluted 1/1000, was added and incubated for
1 hr at RT. The remainder of the assay was as described
for CFAg (section 5.2.13.).
6.2.4. Assay of CRP.
CRP was assayed by a modification of a two-site
sandwich ELISA described by Salonen (1982).
PVC plates were coated with 50pl of polyclonal
anti-CRP (Dako), diluted 1/1000 in 0.1M glycine pH 9.5,
and incubated for 2 hr at RT. Plates were washed and
blocked , before addition of serum samples diluted 1/100,
1/500, 1/1000 and 1/2000 in diluent. CRP standard serum
was purchased from Behringwerke. After overnight
incubation at 4°C, peroxidase-conjugated polyclonal second
antibody, anti-CRP (Dako), diluted 1/1000 , was added and
incubated for 1 hr at RT. The peroxidase was developed as
described earlier (section 5.2.2.).
6.2.5. White cell and neutrophil counts.
These were carried out by routine methods in the
Haematology laboratories of either the Western General




6.3.1. Series 1: Comparison of RIE and ELISA in the assay
of CFAg.
In Series 1 the CFAg concentration was measured by
RIE using anti-CML and ELISA in sera from 37 CF
homozygotes, 17 obligate heterozygotes and 14 normal
healthy controls. The results are shown in Figs.6.1. and
6.2. .
The relationship of the values of CFAg measured by
RIE and ELISA was examined using the Spearman
rank correlation test (Table 6.2.). Highly significant
correlations were found in all three groups of samples.
The difference between the three groups of samples was
tested for significance in both assays by using the Median
test of significance (Table 6.2.). Both RIE and ELISA
showed significant differences between the median values
of all three groups of serum samples. In the more
sensitive ELISA the differences were more significant than
in RIE (p<0.001 compared with p<0.02).
6.3.2. Series 2: CFAg, Lf and CRP values.
Sera from 50 CF homozygotes, 34 CF heterozygotes, 60
healthy controls and 25 disease controls were assayed for
CFAg , Lf and CRP. The results are shown in Figs .6 .3-6.5 . .
For each protein measured there was considerable overlap
between the groups, although the median value of each was
greater for CF homozygotes than CF heterozygotes, which
F1g.6.1. Series 1: Levels of CFAg in serum samples,
measured by RIE7
CF homozygotes (CF), CF heterozygotes (HZ) and
normal controls (N). Median values of each group







Fig.6.2. Series l:Levels of CFAg in serum samples,
measured by ELISA,
CF homozygotes (CF), CF heterozygotes (HZ) and
normal controls (N), measured by ELISA.Median

























Table 6.2. The median values and correlations of RIE and
ELISA of serum samples.
Sample No. RIE ELISA Correlation
mm KU coefficient
Norma 1 14 2 22 0.9782
CF heterozygotes 17 11.5 72 0.7168
CF homozygotes 37 30 250 0.7371
Median test of significance.
RIE Normal/CF heterozygote p<0.02
CF heterozygote/CF homozygote p<0.02
ELISA Normal/CF heterozygote p<0.001
CF heterozygote/CF homozygote p<0.001
Fig.6.3. Series 2: Levels of CFAg in serum samples.
CF homozygotes (CF), CF heterozygotes (HZ),
normal controls (N), and disease controls (DC)
measured by ELISA. Median values of each group
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Fig.6.4. Series 2: Levels of Lf in serum samples.
CF homozygotes (CF), CF heterozygotes (HZ),
normal controls (N), and disease controls (DC)
measured by ELISA. Median values of each group
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Fig.6.5. Series 2: Levels of CRP in serum samples.
CF homozygotes (CF), CF heterozygotes (HZ),
normal controls (N), and disease controls (DC)
measured by ELISA. Median values of each group












































in turn was greater than normal controls. The disease
control group median values were greater than the normal
control group.
The ratio of CFAg to Lf and of CFAg to CRP was
calculated for each sample. Ratios of the samples in the
four groups are plotted in Figs.6.6. and 6.7. The ratios
for the CF heterozygotes were the highest in both sets of
data.
The relationship of the values of CFAg, Lf and CRP in
each sample was examined using the Spearman rank
correlation test. Significant correlations were found for
each pair of proteins in CF homozygotes (Table 6.3.).
Significant differences were also found between CFAg and
Lf in CF heterozygotes and in normal controls, but not in
disease controls.
The difference between the four groups of samples was
tested for significance by comparing the median values of
CFAg, Lf, and CRP, and the median values of the ratios of
CFAg/Lf and CFAg/CRP. Results are shown in Table 6.4..
In all assays the same normal and CF homozygote serum
samples were incorporated as serum standards to assess the
variability of each assay system. The results are
summarised in Table 6.5..
Fig.6.6. Series 2: Ratios of CFAg to Lf in serum samples.
CF homozygotes (CF), CF heterozygotes (HZ),
normal controls (N), and disease controls (DC)
measured by ELISA. Median values of each group

























































Fig.6.7. Series 2: Ratios of CFAg to CRP in serum samples.
CF homozygotes (CF), CF heterozygotes (HZ),
normal controls (N), and disease controls (DC)
measured by ELISA. Median values of each group

















































Table 6.3. Significance of correlations between CFAg, Lf,
and CRP in individual samples from the four
different groups of serum samples. (Spearman
rank test).
CF CF Normal Disease
homozygotes heterozygotes controls controls
CFAg vs Lf p
CFAg vs CRP p






























































































































































































6.3.3. White cell and neutrophil counts.
The white cell (12.6 + 4.1 x 109/1) and neutrophil
g
counts (9.0 + 3.7 x 10 /1) are elevated in CF homozygotes.
The CF heterozygote and disease control groups all had
white cell and neutrophil counts within the normal range;




This study confirms earlier observations using
polyclonal antisera (Manson and Brock, 1980; Bullock et
a 1 ., 1982) that the level of CFAg is elevated in CF
homozygotes, at an intermediate level in CF heterozygotes
and is low in normal controls.
In Series 1, measurement of CFAg by RIE and ELISA
showed highly significant correlations in all three groups
of samples. The medians of all three groups were also
significantly different but there is a considerable
overlap of the RIE peak values in all three groups. In the
ELISA there is overlap between the CF homozygote and CF
heterozygote samples, But only 1 of the 14 normal values
is in the CF range (Fig.6.2.). The ELISA appears to
improve the discrimination of the three CF genotypes
compared with peak area measurement in RIE.
The presence of CFAg in serum originates in
granulocytes (van Heyningen et a 1 ., 1985) i. These cells are
fragile and can release their contents during blood
collection which explains the care which was necessary in
both blood collection and handling previously observed
(Bui lock et a 1 ., 1982). The granulocyte turnover in
normal individuals is very rapid, since a normal adult
releases 1011 neutrophils into the circulation daily
(Baggiolini, 1980). The short time spent by these cells in
the blood means that granulocyte proteins are cleared very
quickly.
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Measurement of another granulocyte protein should
allow the damage taking place in vivo and in vitro to be
assessed. L f, an iron-binding protein present in the
secondary or specific granules of granulocytes
(Baggiolini, 1980; Lash et a 1 . 1983) was chosen as it is
thought to reflect granulocyte activation (Lash et a 1.,
1983). By measuring Lf simultaneously with CFAg in serum
it should be possible to 'correct' for cell damage.
CRP is an indicator of tissue damage in vivo, which
may cause undue elevation of granulocyte proteins (Pepys
and Baltz, 1983). The level of this protein was also
measured in each serum sample.
In Series 2 the observed values of CFAg, Lf and CRP
in serum were compared in the four different groups. The
values of CFAg in serum samples could not safely
distinguish CF homozygotes and heterozygotes from normal
controls and in the case of disease controls, with above
normal levels of CFAg, it was even more difficult. When
each individual sample was compared for ratios of CFAg/Lf
or CFAg/CRP no clear separation was observed. Therefore,
neither of these proteins improved the separation of CF
homozygotes, CF heterozygotes and controls.
This study of CFAg in relation to Lf and CRP was
devised to identify whether the observed levels of CFAg
had any specificity for the CF gene or was purely a result
of granulocyte proliferation or tissue damage due to
infection. The data accumulated does not clarify the
situation.
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The results from CF homozygotes and disease controls
are complicated by the fact that both groups have a
variety of clinical manifestations. The identification of
any possible specificity for CFAg in CF should therefore
be considered in disease-free controls and CF
heterozygotes.
The data for CF heterozygotes shows that whilst the
level of CFAg is significantly elevated compared with
normal controls there is no significant increase in the
levels of either Lf or CRP (Table 6.4.). Consideration of
the ratio of CFAg/Lf further emphasizes this point.
The observation of the elevated CFAg in heterozygotes
can be explained by this being due to a CF gene-specific
component. The CF homozygotes have a two component system,
one contributed to by increased granulocyte turnover
resulting from active infection and the other being gene
specific. The disease controls have increased CFAg due to
the increased active infection indicated by elevated CRP
levels observed.
The results of these assays indicate that CFAg levels
in serum cannot be used as a heterozygote screening test
in a general population. However, the persistent
observation of elevated CFAg in the disease-free CF
heterozygotes suggests that there is some link between




The work described in this thesis was initiated by
reported observations of a CF-specific protein which could
be detected as a doublet band at pi 8.46+0.05 after IEF of
CF homozygote and heterozygote serum (Wilson et a 1.t 1973 ;
1975). This method involved careful collection of blood
and very specific running and staining conditions in order
for the doublet band (CFP) to be observed in the majority
of CF homozygotes and heterozygotes, but not in the
majority of healthy controls. The test was qualitative and
was dependent for success on the observer being able to
identify the band correctly. Many laboratories succeeded
in identifying the doublet band, but with such varying
degrees of success that in most cases the test was not
considered sufficiently accurate to be used as a
diagnostic or carrier test for CF.
A limited quantity of antiserum had been produced in
guinea pigs by immunisation with the homogenised portion
of IEF gel containing the doublet band (Manson and Brock,
1980). The quality of the antiserum was very variable and
only small quantities suitable for serum testing were
available. The antiserum was tested by RIE and showed
quantitative differences dependent on CF genotype, a large
peak in CF homozygotes, an intermediate peak in CF
heterozygotes and a small or absent peak in healthy
controls. The apparent gene dosage effect observed
indicated the possible potential of using this protein in
diagnosis and carrier detection of CF.
In order to test the potential of using the
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polyclonal antiserum produced against the portion of IEF
gel containing the doublet band, a large quantity of
antiserum was required. This was accumulated by immunising
a large number of guinea pigs. Only 40% of the guinea pigs
immunised produced a specific antiserum (anti-IEF) which
showed an apparent quantitative difference of a serum
protein, measured by RIE, in CF homozygotes, CF
heterozygotes and healthy controls. The amount of
antiserum from each guinea pig was small, but by pooling
batches of serum from several guinea pigs sufficient was
available to test a series of serum samples. Two batches
of antiserum, AS60 and AS82/83, were used to assay the
protein in the serum from 14 CF homozygotes, 28 CF
heterozygotes and 23 healthy controls, by RIE and IRMA
(Bullock et a 1 , 1982). Selection of arbitrary cut-offs for
each assay system enabled 94% of the CF genotypes to be
correctly identified.
Some characterisation of the serum protein was
possible using anti-IEF. The protein had an apparent
molecular weight of 51-60 kd as assessed by gel
filtration. Immunodepletion of serum, using commercially
available anti-IgG, followed by RIE showed no reduction of
the antigen peak. Similarly, depletion of the serum with
protein-A sepharose showed no reduction of immunological
activity. These three characteristics of CFAg differed
from reported properties of CFP (Wilson, 1982). Therefore,
the protein identified by anti-IEF was named cystic
fibrosis antigen (CFAg). Attempts to purify CFAg from CF
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serum by immunopurification, using anti-IEF, were
unsuccesfu 1.
The use of anti-IEF showed discrimination between the
three different CF genotypes, but the the quality and
quantity of this antiserum was extremely difficult to
control.
In a search for a rich source of CFAg, which would
hopefully make antiserum production easier, a variety of
easily accessible cells and body fluids were tested, using
anti-IEF. The only material, other than serum, containing
detectable quantities of CFAg was the cytoplasmic fraction
of granulocytes. Very high levels of CFAg were found in
granulocytes from CF homozygotes, CF heterozygotes,
healthy normals and CML patients. Identification of CML
granulocytes as an abundant source of CFAg enabled the
production of a high titre antiserum in guinea pigs. This
antiserum (anti-CML) showed complete identity with
anti-IEF when tested by Ouchterlony double diffusion
against both CF serum and CML granulocyte lysate.
A cellular source of CFAg allowed for the production
of somatic cell hybrids between a mouse stem-cell line and
CML granulocytes. Segregation analysis of the hybrids
assigned the gene for CFAg to chromosome 1 (van Heyningen
et al., 1985).
Development of an immunoassay for a CF-associated
serum protein is an improvement on the observer dependent
IEF method and appears to classify a larger number of
serum samples correctly. However the immunoassay is not
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very sensitive and will not detect low levels or small
differences of CFAg accurately.
Hybridoma culture techniques allowed for the
production of monoclonal antibodies against CFAg (Hayward
et a 1 ., 1986). These antibodies were initially identified
by screening against CML granulocyte lysate. Their
immunospecificity was verified by their ability to
immunodeplete the CFAg peak from CF serum, when tested
against anti-IEF. The ten stable hybridomas produced were
further identified as being against the same protein as
anti-IEF and anti-CML by immunoprecipitation of antigen
from radiolabelled CML granulocytes. SDS-polyacrylamide
electrophoresis of the specific immunoprecipitates showed
two common bands of MW 14kd and 11.5kd.
Selection of a suitable pair of monoclonal antibodies
allowed for the development of a sensitive, reproducible
two-site sandwich ELISA for CFAg. A standard curve was
derived using dilutions of a CML granulocyte lysate given
an arbitrary value for CFAg of 10^U/ml of lysate
O
(10 eel Is/ml). The assay was sensitive over a wide range
of serum dilutions and therefore was suitable for rapid,
large scale measurement of CFAg.
Preliminary testing of the ELISA in a series of serum
samples from 37 CF homozygotes, 17 CF heterozygotes and 14
healthy controls in comparison with RIE, using anti-CML,
showed a highly significant correlation between both sets
of results. There was overlap between the three groups of
samples in both assays, but the median values were
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significantly different.
The location of granulocytes as the source of CFAg
indicated that there was a possibility that the raised
levels of CFAg in serum from CF homozygotes and
heterozygotes was due to granulocyte proliferation. This
possiblity was tested for by measuring CFAg, by ELISA, in
a second series of samples, consisting of 50 CF
homozygotes, 34 CF heterozygotes, 60 healthy controls and
25 patients suffering from non-CF related respiratory
disorders. Another granulocyte-derived serum protein, Lf,
and the acute-phase reactant CRP were measured
simultaneously (Hayward et a 1.).
In these assays it was impossible to distinguish the
four groups of samples by measuring CFAg. The median
values for the CF homozygotes compared with CF
heterozygotes and CF heterozygotes compared with healthy
controls were still significantly different, but the
disease controls were not significantly different from the
CF heterozygotes. Consideration of the ratios of CFAg/Lf
and CFAg/CRP did not improve the discrimination of
samples. However, the ratio of CFAg/Lf in the healthy CF
heterozygotes was significantly greater than in the other
three groups. The elevated level of CFAg in serum is not
related to an increase in granulocyte number and may
indicate a possible association between CFAg and the CF
gene.
The production of monoclonal antibodies and the
development of an ELISA has greatly improved the
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reproducibi1ity, accuracy and sensitivity of the detection
of CFAg. The overlap of antigen values observed in earlier
assays is still apparent and the reason for this must be
due to biological, rather than technical, phenomena.
Once monoclonal antibodies were produced against CFAg
it was thought worthwhile to purify the protein and
determine its biochemical identity. While the assay system
was being developed and assessed other members of our CF
research group undertook the task of purifying and
characterising CFAg.
The monoclonal antibodies to CFAg were used to
immunopurify the protein (Novak et a 1.).
CFAg was found to be inducible in the pro-myelocytic
cell line HL60 using either retinoic acid (RA) or dimethyl
sulphoxide (DMSO) to cause differentiation along the
myeloid pathway (Collins et a 1 ., 1977 ).
One monoclonal antibody (CF557) was used for
immunoaffinity purification of CFAg from CF plasma,
granulocytes and induced HL60 cells. Purified protein from
all sources was found to be identical by amino-acid
sequencing for at least the first 20 residues.
The molecular mass of the CFAg subunit has been
defined as approximately 14kd by specific
immunoprecipitation from *^I-labelled CML granulocyte
lysate. Using specific immunoprecipitation following the
incorporation of S-methionine into proteins in intact
cells in culture, CFAg synthesis was shown in normal and
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CML granulocytes and in differentiated HL60 cells,
identifying three available sources of mRNA.
The partial amino-acid sequencing of CFAg allowed the
synthesis of a highly redundant oligonucleotide probe
which was able to isolate a cDNA clone (CFA 8-9) from a
library constructed in /g110 using mRNA prepared from CML
granulocytes (Dorin et a 1 ., 1987 ).
The nucleotide sequence of CFA 8-9 encoded 83
amino-acids from the first amino-acid of the
oligonucleotide to the C-terminal residue. The sequence of
the first 11 amino-acids was derived from the protein
sequencing. A relative molecular mass of 10,938 was
deduced from the 94 amino-acid sequence.
Northern blot analysis on a variety of tissues and
cell lines was carrried out to assess message size and
abundance. mRNA from CML granulocyte samples contained
very high levels of CFA 8-9 transcripts with a major band
of approximately 550 base pairs (bp) and a minor band of
approximately 1000 bp. Equivalent amounts of mRNA isolated
from uninduced HL60 and from RA and DMSO induced HL60
showed no message in uninduced, low abundance in RA
induced and high abundance in DMSO induced HL60 cells.
mRNA from other malignant cell lines gave no detectable
signal.
Southern blot analysis of somatic cell hybrids
between WEHI-TG and human CML cells only showed a positive
signal in the presence of chromosome 1. The availability
of cell hybrids containing defined fragments of chromosome
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1 allowed the gene locus to be localised to the region
between bands q12 and q22 on the long arm of chromosome 1.
The deduced amino-acid sequence of cloned CFAg was
compared with sequences in an NBRF database. Highly
significant homology was obtained with the subunits of a
brain associated calcium-binding protein, bovine SlOOa and
SlOOb (Isobe and Okuyama, 1981) and bovine, porcine and
rat Intestinal calcium-binding proteins (Fullmer and
Wassermann, 1981). Two other ca1cium-binding proteins,
porcine p11, a regulatory subunit of the protein complex
which is a cellular target for tyrosine kinase (Gerke and
Weber, 1985; Glenney and Tack, 1985) and 2A9, also known
as calcyclin, a protein that shows cell cycle dependent
expression in WI-38 cells (a strain of human diploid
fibroblasts (Calabretta et a 1 .,1986; Ferarri et a 1.,
1987). Calcyclin is not detectable in quiescent
fibroblasts, but can be stimulated to express in cells
treated with serum, platelet-derived growth factor or
epidermal growth factor. It can also be induced in a wide
variety of other cells including acute myeloid leukaemia
(AML) and CML. In some AML cells it appears to be
deregulated and a possible role in cell-cycle regulation
has been postulated for calcyclin. The gene for calcyclin
has been mapped, by in situ hybridisat i on to the long arm
of chromosome 1 q21 -q25 (Ferrari et a 1 ., 1987). Calcyclin
is the only homologous protein to CFAg which has, so far,
been mapped to a chromosome. The close proximity to the
two gene locations indicates a possible gene cluster for
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this family of calcium-binding proteins.
Despite development of the best possible assay system
and characterisat ion of the gene, it is still not possible
to ascertain whether CFAg has a role in CF. The generally
elevated level of CFAg observed in serum from healthy CF
heterozygotes compared with healthy controls indicates
some connection with expression of the CF gene but at
present the physiolo1ogica 1 or biochemical mechanism
responsible for this is unknown.
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